MAGE-A1 specific T cell receptor and application thereof

By developing tumor-specific TCRs that specifically bind to the MHC/MAGE-A1 epitope, the problems of limited antigen specificity and severe off-target effects in existing adoptive lymphocyte therapies have been solved, achieving highly efficient killing of MAGE-A1-expressing cancer cells and a safe adoptive cell therapy.

CN119019533APending Publication Date: 2024-11-26HRYZ (SHANGHAI) BIOTECH CO +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411196852.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Current adoptive lymphocyte therapy for cancer treatment faces problems such as limited antigen-specific mutations, frequent adverse events in clinical trials, and serious off-target effects. In particular, targeted TCR therapy against the MAGE-A1 antigen has problems with central nervous system toxicity and T cell population biased proliferation.

Method used

A tumor-specific T-cell receptor (TCR) that specifically binds to the major tissue compatibility complex (MHC)/MAGE-A1 epitope has been developed, comprising specific amino acid sequences of the TCRα and TCRβ chains, for use in engineering immune cells to enhance anti-tumor efficacy and reduce off-target effects, and for adoptive cell therapy via genetically modified T cells expressing the MAGE-A1-specific TCR.

Benefits of technology

It achieves highly efficient killing of MAGE-A1-expressing cancer cells, reduces off-target effects and central nervous system toxicity, improves the specificity and safety of treatment, and provides an effective means of cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019533A_ABST
    Figure CN119019533A_ABST
Patent Text Reader

Abstract

The present invention provides tumor specific T cell receptors that specifically bind to the major histocompatibility complex (MHC) / MAGE-A1 epitope complex, engineered T cells comprising the receptors, and methods of using the same to treat diseases, including cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of cancer immunotherapy. Specifically, the present application relates to binding molecules in some aspects, such as complexes capable of specifically binding to major histocompatibility complex (MHC) molecules and MAGE-A1 peptides. In particular, the present application relates to T cell receptors (TCRs) that bind or recognize such peptide epitopes, including their antigen binding domains. The present application further relates to engineered cells comprising such binding molecules, such as TCRs, and their use in adoptive cell therapy. Background Art

[0002] The human body has a complex immune system to protect itself from diseases, including malignant tumors in the body. The natural immune response to tumors is usually triggered by tumor antigens, including mutant proteins that are specifically expressed in cancer cells, and tumor-associated antigens (TAAs) that are overexpressed in cancer-origin tissues but cannot be fully recognized as "self". Antigen-presenting cells (APCs) (especially dendritic cells (DCs)) that encounter tumor antigens can process tumor antigens and present them on their cell surfaces. After maturation, DCs loaded with tumor antigens can cause T cell responses to cancer cells that host tumor antigens, involving cytotoxic T cells, helper T cells, and functionally different effector T cells and memory T cells. Cytotoxic T cells can specifically bind to and recognize cancer cells expressing tumor antigens through their surface T cell receptors (TCRs), and kill cancer cells by releasing cytokines, enzymes, and cytotoxins or by initiating pro-apoptotic signal cascades via cell-cell interactions.

[0003] Adoptive lymphocyte therapy (ACT) offers a promising concept for cancer treatment by administering ex vivo expanded lymphocytes to a subject. For example, tumor infiltrating lymphocytes (TILs) can be isolated from a patient's tumor, expanded ex vivo, and infused back into the patient after removal of the patient's natural non-myeloid lymphocytes. However, the variability in the affinity of TILs isolated from each patient or donor limits the anti-tumor efficacy in clinical trials. In addition, most antigen-specific mutations that lead to immune responses are only found in an individual's cancer, not in multiple patients.

[0004] Engineered T cells containing tumor antigen-specific T cell receptors (TCRs) can overcome some of the challenges faced by current adoptive lymphocyte therapy approaches because it can rapidly generate tumor-reactive T lymphocytes with defined antigen specificity. There is a need for TCRs that target different tumor antigens and provide high antitumor efficacy in vivo and low off-target effects. Common problems with TCR-T cell therapy approaches include serious adverse events (such as central nervous system toxicity) in clinical trials, which may be related to inappropriate target selection (the so-called on-target off tumor effect) and biased expansion of T cell populations.

[0005] Melanoma-associated antigen A1 (MAGE-A1) is a cancer-testis antigen that exists in adult male germ cells and embryonic cells and plays an important role in tumor detection and immunotherapy. The MAGE-A1 gene belongs to the MAGE family, which can be divided into two categories: class I and class II. The former is located on the X chromosome and is an important component of tumor-associated antigens, including MAGE-A, MAGE-B and MAGE-C. Among them, the MAGE-A1 gene is only expressed in genomic unstable and easily demethylated tissues such as normal testicular tissue and various tumor tissues, and this gene is considered to be closely related to tumor progression and poor prognosis. The results of the study showed that tumors and / or tumor-derived factors in individuals with genetic susceptibility to autoimmunity may induce myopathy, and the immune response to myositis antigens may be related to the patient's initial or subclinical anti-tumor response. MAGE-A1-specific TCR and TCR-T are therefore promising cancer therapies with high anti-tumor efficacy and low off-target effects. SUMMARY OF THE INVENTION

[0007] According to a first aspect of the present invention, a separated tumor-specific T cell receptor (TCR) or its antigen-binding domain that specifically binds to a major histocompatibility complex (MHC) / MAGE-A1 epitope complex is provided, wherein the tumor-specific TCR comprises: a TCR α chain, wherein the TCR α chain comprises a CDR1 having an amino acid sequence of SEQ ID NO:1, a CDR2 having an amino acid sequence of SEQ ID NO:2, and a CDR3 having an amino acid sequence of SEQ ID NO:3; and a TCR β chain, wherein the TCR β chain comprises a CDR1 having an amino acid sequence of SEQ ID NO:4, a CDR2 having an amino acid sequence of SEQ ID NO:5, and a CDR3 having an amino acid sequence of SEQ ID NO:6.

[0008] In some embodiments, an isolated tumor-specific TCR or antigen binding domain thereof that specifically binds to a major histocompatibility complex (MHC) / MAGE-A1 epitope complex is provided, wherein the MAGE-A1 epitope comprises the amino acid sequence shown in SEQ ID NO:79.

[0009] In some embodiments according to any of the above, the MHC is HLA-A*11:01.

[0010] In some embodiments according to any of the above, the isolated tumor-specific TCR or its antigen-binding domain comprises: a TCR α chain comprising a variable region having an amino acid sequence of SEQ ID NO:7 and a TCR β chain comprising a variable region having an amino acid sequence of SEQ ID NO:10.

[0011] In some embodiments according to any of the above, the isolated tumor-specific TCR or antigen-binding domain thereof comprises:

[0012] A TCR alpha chain comprising an amino acid sequence having SEQ ID NOs: 7 and 8 or an amino acid sequence having at least 90% sequence identity thereto, and a TCR beta chain comprising an amino acid sequence having SEQ ID NOs: 10 and 11 or an amino acid sequence having at least 90% sequence identity thereto.

[0013] According to some of the above embodiments, the isolated TCR or antigen binding domain thereof is isolated or purified or recombinant.

[0014] According to some of the above embodiments, the isolated TCR or antigen binding domain thereof is chimeric, humanized or human.

[0015] According to any of the above embodiments, the isolated TCR or antigen binding domain thereof is a single chain.

[0016] According to some of the above embodiments, the isolated TCR or antigen binding domain thereof, wherein the TCR α chain further comprises an α constant (Cα) region and / or the TCR β chain further comprises a β constant (Cβ) region.

[0017] According to any of the above embodiments, the isolated TCR or antigen binding domain thereof, wherein the Ca region and the Cβ region are mouse constant regions.

[0018] According to some of the embodiments of any of the above, the isolated TCR or its antigen binding domain, wherein the Cα region comprises the amino acid sequence of SEQ ID NOs: 22 or an amino acid sequence having at least 90% sequence identity thereto, and / or the Cβ region comprises the amino acid sequence of SEQ ID NOs: 25 or an amino acid sequence having at least 90% sequence identity thereto.

[0019] According to some of the embodiments of any of the above, the isolated TCR or its antigen binding domain comprises: a TCR alpha chain comprising an amino acid sequence having SEQ ID NOs: 21 and 22 or an amino acid sequence having at least 90% sequence identity therewith, and a TCR beta chain comprising an amino acid sequence having SEQ ID NOs: 24 and 25 or an amino acid sequence having at least 90% sequence identity therewith.

[0020] According to any one of the above embodiments, the isolated TCR or antigen binding domain thereof, wherein the TCR alpha chain and / or the TCR beta chain further comprises a signal peptide.

[0021] In some embodiments, an isolated nucleic acid is provided that encodes an isolated TCR or antigen binding domain thereof or a TCR alpha chain or TCR beta chain thereof according to any of the above embodiments.

[0022] The isolated nucleic acid molecule according to any of the above embodiments, wherein the nucleic acid sequence is codon optimized.

[0023] The isolated nucleic acid molecule according to any of the above embodiments, wherein the nucleotide sequence encoding the TCR alpha chain and the nucleotide sequence encoding the TCR beta chain are separated by a self-cleaving peptide sequence.

[0024] The isolated nucleic acid molecule according to any of the above embodiments, wherein the self-cleaving peptide is P2A, comprising the amino acid sequence shown in SEQ ID NO:13.

[0025] In some embodiments, an isolated nucleic acid is provided, the isolated nucleic acid encoding the TCR alpha chain and the TCR beta chain of the tumor-specific TCR of any one of claims 1-13.

[0026] In some embodiments, an engineered immune cell is provided, wherein the engineered immune cell comprises a tumor-specific TCR or a nucleic acid encoding the same as described in any of the above embodiments, wherein the engineered cell is a cell line or a primary cell or an allogeneic cell obtained from a subject, preferably, the cell is a human cell, including but not limited to T cells, NK cells, macrophages, etc.

[0027] The engineered immune cell according to any of the above embodiments, wherein the immune cell is a T cell.

[0028] The engineered cell according to any of the above embodiments, wherein the engineered cell comprises a CD8+ T cell.

[0029] The engineered cell according to any of the above embodiments, wherein the engineered cell comprises a CD4+ T cell.

[0030] In some embodiments, a pharmaceutical composition is provided, comprising the engineered immune cell described in any one of the above embodiments, and a pharmaceutically acceptable carrier.

[0031] In some embodiments, a method of treating a disease or disorder expressing MAGE-A1 is provided, comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition according to any one of the above embodiments.

[0032] The method according to any of the above embodiments, wherein the disease or disorder is cancer.

[0033] The method according to any of the above embodiments, wherein the cancer is selected from lung cancer, liver cancer, skin cancer, breast cancer and head and neck tumors.

[0034] The method according to any of the above embodiments, wherein the engineered cells are autologous cells of the subject.

[0035] The method according to any of the above embodiments further comprises administering to the subject one or more of the following: immunosuppressants, therapeutic antibodies, chemotherapy, radiation therapy, surgery, or any combination thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] The following examples are intended to be purely illustrative of the present patent application and therefore should not be considered to limit the invention in any way.The following examples and detailed description are provided by way of illustration and not by way of limitation.

[0037] Figure 1 The present invention shows MAGE-A1 specific TCR constructions (wild type, murinized, and murinized codon-optimized constructs).

[0038] Figure 2-4 Screening and characterization of T cells expressing the MAGE-A1 antigen-specific T cell receptor HRYZ-TCR-4.12 are shown.

[0039] Figure 5Shown is the HLA restriction assay of T cells expressing the MAGE-A1 antigen-specific T cell receptor HRYZ-TCR-4.12 in the LCL cell line.

[0040] Figure 6 It was shown that T cells expressing the MAGE-A1 antigen-specific T cell receptor HRYZ-TCR-4.12 were cytotoxic to the A549 cell line that was double positive for HLA-A*11:01 and MAGE-A1 protein in vitro. DETAILED DESCRIPTION OF THE INVENTION

[0042] I. Definitions

[0043] Before describing the present invention in detail with respect to some preferred embodiments thereof, the following general definitions are provided. Unless otherwise defined below, terms are used herein as commonly used in the art.

[0044] The present invention will be described with respect to specific embodiments and with reference to certain drawings, but the invention is not limited thereto, but only by the claims. When the term "comprising" is used in this specification and in the claims, it does not exclude other elements. For the purposes of the present invention, the term "consisting of" is considered a preferred embodiment of the term "comprising". If a group is defined hereinafter as comprising at least a certain number of embodiments, it should also be understood to disclose a group that preferably consists of only these embodiments.

[0045] For the purposes of the present invention, the term “obtained” is considered to be a preferred embodiment of the term “obtainable.” If in the following, for example an antibody is defined as being obtainable from a particular source, this is also to be understood as disclosing the antibody obtained from this source.

[0046] As used herein, "T cell receptor" or "TCR" refers to an endogenous or engineered T cell receptor that includes an extracellular antigen binding domain that binds to a specific antigen epitope in an MHC molecule. TCR may include a TCR alpha polypeptide chain and a TCR beta polypeptide chain. "Tumor-specific TCR" refers to a TCR that specifically recognizes a tumor antigen expressed by a tumor cell. "TCR-T" refers to a T cell that expresses a recombinant TCR. The "antigen binding domain" of a TCR refers to a polypeptide that the TCR specifically binds to an antigen with a higher degree of specificity due to its primary, secondary or tertiary sequence and / or post-translational modification and / or charge. The antigen binding domain may be derived from any part or fragment of a TCR that retains the antigen binding activity of the TCR as part of the TCR. The antigen binding portion encompasses, for example, a portion of a TCR that retains specific binding to an amino acid sequence of MAGE-A1 or a fragment thereof, or a portion of the ability to detect, treat or prevent cancer to a similar degree, the same degree or a higher degree than a wild-type TCR. The TCR antigen binding domain may comprise, for example, about 10%, about 25%, about 30%, about 50%, about 68%, about 80%, about 90%, about 95% or more of the full-length TCR. The antigen binding domain may comprise an antigen recognition portion of any one or both of the α chain and β chain of the TCR, such as one or more of the complementary determining regions CDR1, CDR2 and CDR3 of the variable region of the α chain and / or β chain of the TCR. The antigen binding domain may comprise the following amino acid sequence: CDR1 of the α chain, CDR2 of the α chain, CDR3 of the α chain, CDR1 of the β chain, CDR2 of the β chain, CDR3 of the β chain, or any combination thereof. Preferably, the antigen binding domain comprises the amino acid sequence of CDR1, CDR2 and CDR3 of the α chain of the TCR or the amino acid sequence of CDR1, CDR2 and CDR3 of the β chain; or the amino acid sequence of CDR1, CDR2 and CDR3 of all α chains and β chains. In one embodiment of the invention, the antigen binding portion may include, for example, a variable region of a TCR, which includes a combination of the above-mentioned CDR regions. In this regard, the antigen binding portion may include an amino acid sequence of the variable region (Vα) of the α chain of the TCR, an amino acid sequence (Vβ) of the variable region of the β chain, or an amino acid sequence of both Vα and Vβ. In one embodiment of the invention, the antigen binding portion may include a combination of a variable region and a constant region. In this regard, the antigen binding portion may include the full length α or β chain of the TCR, or both α and β chains.

[0047] As used herein, "immune checkpoint inhibitors" refer to agents (including antibodies) that inhibit or block inhibitory immune checkpoint molecules on immune cells (such as T cells) or tumor cells. "Immune checkpoint molecules" include molecules that enhance immune signals to tumor cells (i.e., "co-stimulatory molecules"), or molecules that reduce immune signals to tumor cells (i.e., "inhibitory immune checkpoint molecules").

[0048] As used herein, "treatment" is a way to obtain beneficial or desired results (including clinical results). For the purposes of the present invention, beneficial or desired clinical results include, but are not limited to, one or more of the following: reducing the symptoms caused by another disease, reducing the degree of the disease, stabilizing the disease (e.g., preventing or delaying the deterioration of the disease), preventing or delaying the spread of the disease (e.g., metastasis), preventing or delaying the occurrence or recurrence of the disease, delaying or slowing down the progress of the disease, improving the disease state, providing (partial or complete) relief of the disease, reducing the dosage of one or more other drugs required for treating the disease, delaying the progress of the disease, increasing the quality of life, and / or prolonging survival. "Treatment" also encompasses the reduction of the pathological results of diseases (such as cancer). The method of the present invention contemplates any one or more of these treatment aspects.

[0049] As used herein, an "isolated" construct (e.g., MAGE-A1 TCR) refers to a construct that (1) is not related to proteins found in nature, (2) does not contain other proteins from the same source, (3) is expressed by cells from a different species, or (4) does not occur in nature.

[0050] As used herein, the term "isolated nucleic acid" is intended to mean a nucleic acid of genomic, cDNA, or synthetic origin, or some combination thereof, by virtue of which the "isolated nucleic acid" (1) is not associated with all or a portion of the polynucleotides of the "isolated nucleic acid" found in nature, (2) is operably linked to a polynucleotide to which it is not linked in nature, or (3) does not occur as part of a larger sequence in nature.

[0051] As used herein, "delaying" the development of a disease (such as cancer) means postponing, hindering, slowing down, postponing, stabilizing, and / or delaying the development of a disease. This delay can be of different lengths of time, depending on the history of the disease and / or the individual being treated. As is apparent to those skilled in the art, a sufficient or significant delay can actually encompass prevention, because the individual will not develop the disease. A method of "delaying" the development of a disease (such as cancer) is a method of reducing the likelihood of disease development in a given period of time and / or reducing the extent of the disease in a given period of time when compared to when the method is not used. This simulation is more generally based on clinical studies, using a statistically significant number of individuals. Standard methods can be used to detect cancer development, including but not limited to computed tomography (CAT scans), magnetic resonance imaging, abdominal ultrasound, coagulation tests, arterial photography, or biopsy. Development can also refer to cancer progression that may initially be undetectable, and includes occurrence, recurrence, and onset.

[0052] The terms "subject," "subject," and "patient" are used interchangeably herein to describe mammals, including humans. Subjects include, but are not limited to, humans, cattle, horses, cats, dogs, rodents, or primates. In some embodiments, the subject is a human. In some embodiments, the subject suffers from a disease such as cancer. In some embodiments, the subject is in need of treatment.

[0053] As is understood in the art, an "effective amount" refers to an amount of a composition (e.g., an engineered immune cell expressing a TCR) sufficient to produce a desired therapeutic outcome (e.g., reducing the severity or duration of one or more cancer symptoms, stabilizing the severity of one or more cancer symptoms, or eliminating one or more cancer symptoms). For therapeutic use, beneficial or desired results include, for example, reducing one or more symptoms (biochemical, histological, and / or behavioral) caused by the disease, including complications and intermediate pathological phenotypes presented during the development of the disease; increasing the quality of life of those suffering from the disease; reducing the dose of other drugs required to treat the disease; enhancing the effect of another drug; delaying the progression of the disease; and / or prolonging the survival of the patient.

[0054] "Adjuvant therapy" refers to a clinical setting in which an individual already has a history of cancer and has typically (but not necessarily) responded to therapy, including, but not limited to, surgery (e.g., surgical resection), radiation therapy, and chemotherapy. However, due to their history of cancer, these individuals are considered to be at risk for developing the disease. The treatment or administration in "adjuvant therapy" refers to a subsequent treatment mode. The degree of risk (e.g., when an individual in adjuvant therapy is considered "high risk" or "low risk") depends on a number of factors, the most common being the extent of the disease at the time of the first treatment.

[0055] "Neoadjuvant therapy" refers to the clinical setting in which the approach is given prior to primary / definitive therapy.

[0056] As used herein, "combination therapy" means that the first agent is administered in conjunction with another agent. "In conjunction with" refers to the administration of a treatment modality in addition to another treatment modality, such as a composition described herein (e.g., an engineered immune cell expressing a TCR) is administered to the same individual in addition to the administration of another agent (such as an immune checkpoint inhibitor). Therefore, "in conjunction with" refers to the administration of a treatment modality before, during, or after another treatment modality is delivered to an individual. Such combinations are considered to be part of a single treatment regimen.

[0057] As used herein, the term "simultaneous administration" means that the first therapy and the second therapy in the combination therapy are administered with a time interval of no more than about 15 minutes (such as no more than about 10, 5, or 1 minute). When the first therapy and the second therapy are administered simultaneously, the first therapy and the second therapy can be contained in the same composition (e.g., a composition including both the first therapy and the second therapy) or in different compositions (e.g., the first therapy is in one composition and the second therapy is contained in another composition).

[0058] As used herein, the term "sequential administration" means that the first therapy and the second therapy in the combination therapy are administered with a time interval of more than about 15 minutes, such as more than about any of 20, 30, 40, 50, 60, or more minutes. The first therapy or the second therapy may be administered first. The first therapy and the second therapy may be contained in different compositions, and such different compositions may be contained in the same or different packages or kits.

[0059] As used herein, the term "concurrent administration" means that the administration of a first therapy and the administration of a second therapy in the combination therapy overlap with each other.

[0060] As used herein, "pharmaceutically acceptable" or "pharmacologically compatible" means a material that is not biologically or otherwise undesirable, for example, the material can be incorporated into a pharmaceutical composition administered to a subject without causing any significant undesirable biological effect, or interacting in a deleterious manner with any other component of the composition containing it. Pharmaceutically acceptable carriers or excipients preferably have met the required toxicological testing standards and manufacturing testing standards, and / or are included in the inactive ingredient guide prepared by the U.S. Food and Drug Administration.

[0061] The following definitions can be used to assess target lesion-based responses: “complete response” or “CR” means disappearance of all target lesions; “partial response” or “PR” means a reduction of at least 30% in the sum of the longest diameters of target lesions, with the baseline SLD as reference; “stable disease” or “SD” means a reduction in target lesions that is insufficient to qualify as a PR and an increase that is insufficient to qualify as a PD, with the nadir SLD recorded since the start of treatment as reference; and “progressive disease” or “PD” means an increase in the SLD of target lesions of at least 20% (with the nadir SLD recorded since the start of treatment as reference), or the presence of one or more new lesions.

[0062] The following response assessment definitions can be used to assess non-target lesions: “complete response” or “CR” refers to the disappearance of all non-target lesions; “stable disease” or “SD” refers to the persistence of one or more non-target lesions that do not meet the criteria for CR or PD; and “progressive disease” or “PD” refers to “unequivocal progression” of existing non-target lesion(s), or the appearance of one or more new lesions is considered disease progression (if an individual’s PD is assessed for a time point solely based on progression of non-target lesion(s), additional criteria need to be met).

[0063] As used herein, the terms "cell," "cell line," and "cell culture" are used interchangeably, and all such designations include progeny. It is understood that all progeny may not have exactly the same DNA content due to artificial or accidental mutations. Variant progeny having the same function or biological activity as the original cell are included.

[0064] As used herein, the terms "specifically bind to," "recognize," "specifically recognize," "target," or "specific for" refer to a measurable and reproducible interaction, such as binding between a target and an antibody, or between a receptor and a ligand, or between a receptor and an epitope / MHC complex, that determines the presence of a target in the presence of a heterogeneous population of molecules (including biomolecules). For example, a TCR that binds to or specifically binds to a target epitope is a TCR that binds to the target epitope / MHC complex with greater affinity, binding, more readily, and / or for a longer duration than it binds to other epitopes / MHC complexes. In one embodiment, the extent of binding of a TCR to an unrelated epitope / MHC complex is less than about 10% of the binding of the TCR to the target epitope / MHC complex, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, a TCR that specifically binds to a target epitope (i.e., a target epitope / MHC complex) has a dissociation constant (Kd) of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM. In certain embodiments, a TCR specifically binds to an epitope on a protein that is conserved among proteins from different species. In another embodiment, specific binding may include but does not require exclusive binding.

[0065] As used herein, the term "isolated nucleic acid" is intended to mean a nucleic acid of genomic, cDNA, or synthetic origin, or some combination thereof, which, by virtue of its origin, (1) is not associated with all or part of a polynucleotide in which the "isolated nucleic acid" is found in nature, (2) is operably linked to a polynucleotide to which it is not linked in nature, or (3) does not occur in nature as part of a larger sequence.

[0066] It is understood that aspects and embodiments of the present invention described herein include "consisting of" and / or "consisting essentially of" aspects and embodiments.

[0067] "About" a value or parameter mentioned herein includes (and describes) variations about the value or parameter itself. For example, description referring to "about X" includes description of "X".

[0068] As used herein, the term "about X to Y" has the same meaning as "about X to about Y."

[0069] As used herein, reference to "not" a value or parameter generally means and describes a value or parameter "other than." For example, the method is not used to treat type X cancer means that the method is used to treat types other than X cancer.

[0070] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0071] II. MAGE-A1 Tumor-Specific TCR

[0072] The present application provides a TCR that specifically recognizes tumor MAGE-A1 and / or specifically recognizes an MHC / MAGE-A1 epitope complex. In some embodiments, the tumor-specific TCR specifically recognizes MAGE-A1. In some embodiments, the tumor-specific TCR specifically recognizes an MHC / MAGE-A1 epitope complex. Nucleic acids and vectors encoding tumor-specific TCRs, and engineered immune cells expressing tumor-specific TCRs are also within the scope of the present patent application.

[0073] Exemplary TCRs identified using the methods described herein are shown in Table 1 below. The V, J, and C segments are named according to the IMGT database. Other nomenclature and segment delineation algorithms known in the art may be used. See, for example, Lefranc, M.-P., The Immunologist, 7, 132-136 (1999), and world wideweb.imgt.org / IMGTScientificChart / Nomenclature / IMGT-FRCDRdefinition.html. The CDR1, CDR2, and CDR3 of an exemplary TCR are shown in the "Sequence Listing" section.

[0074] Table 1: Exemplary tumor-specific TCRs

[0075]

[0076] In some embodiments, a MAGE-A1 tumor-specific TCR or an antigen binding domain thereof is provided, which specifically binds to an epitope of a MAGE-A1 peptide, such as a MAGE-A1 epitope comprising the amino acid sequence of SEQ ID NO: 79. In some embodiments, a MAGE-A1 tumor-specific TCR or an antigen binding domain thereof specifically binds to an MAGE-A1 epitope comprising the amino acid sequence of SEQ ID NO: 79. In some embodiments, a MAGE-A1 tumor-specific TCR or an antigen binding domain thereof is provided, which specifically binds to a MAGE-A1 peptide / MHC complex, wherein MAGE-A1 comprises an MAGE-A1 epitope comprising the amino acid sequence of SEQ ID NO: 79. In some embodiments, the MHC protein in the MAGE-A1 peptide / MHC complex is an MHC-I class protein. In some embodiments, the MHC-I class protein is HLA-A. In some embodiments, HLA-A is HLA-A*11:01. In some embodiments, the target antigen of the effector cell (eg, T cell) expressing MAGE-A1 tumor-specific TCR or its antigen-binding domain on its surface is MAGE-A1 96-104 Peptide / MHCI A*11:01 complex.

[0077] In some embodiments, a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof is provided, which comprises the amino acid sequence of any one of SEQ ID NOs: 3, 6, 17, 20, 31, and 34. In some embodiments, a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof is provided, which includes: (a) a TCRα CDR3 having at least about 90% sequence identity (e.g., 100% identity) to SEQ ID NO: 3; and a TCRβ CDR3 having at least about 90% sequence identity (e.g., 100% identity) to SEQ ID NO: 6; (b) a TCRα CDR3 having at least about 90% sequence identity (e.g., 100% identity) to SEQ ID NO: 17; and a TCRβ CDR3 having at least about 90% sequence identity (e.g., 100% identity) to SEQ ID NO: 20; (c) a TCRα CDR3 having at least about 90% sequence identity (e.g., 100% identity) to SEQ ID NO: 31; and a TCRβ CDR3 having at least about 90% sequence identity (e.g., 100% identity) to SEQ ID NO: 32. NO:34 A MAGE-A1 tumor-specific TCR or its antigen-binding domain having an amino acid sequence with at least about 90% sequence identity (e.g., 100% identity) has higher affinity.

[0078] In some embodiments, a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof is provided, which includes a TCR α chain including CDR1, CDR2, and CDR3 of any one of the amino acid sequences of SEQ ID NO: 9, 23, or 37.

[0079] In some embodiments, a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof is provided, which includes a TCR β chain including CDR1, CDR2, and CDR3 of any one of the amino acid sequences of SEQ ID NO: 12, 26, or 40.

[0080] In some embodiments, a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof is provided, comprising: a TCR α chain comprising the CDRs of any one of the amino acid sequences of SEQ ID NO: 9, 23, or 37; and a TCR β chain comprising the CDRs of any one of the amino acid sequences of SEQ ID NO: 12, 26, or 40.

[0081] The tumor-specific TCR or its antigen-binding domain described herein also includes a TCR constant domain. In some embodiments, the tumor-specific TCR or its antigen-binding domain includes: a TCR alpha chain including a TCR alpha constant domain (TRAC) of any one of SEQ ID NO: 9, 23, 37, or a variant thereof; and a TCR beta chain including a TCR beta constant domain (TRBC) of any one of the amino acid sequences of SEQ ID NO: 12, 26, 40, or a variant thereof. In some embodiments, the tumor-specific TCR or its antigen-binding domain includes: human TRAC and human TRBC, such as human Cα and human Cβ1, or human Cα and human Cβ2. In some embodiments, the tumor-specific TCR or its antigen-binding domain includes murine TRAC and murine TRBC, such as murine Cα and murine Cβ1, or murine Cα and murine Cβ2.

[0082] In some embodiments, the MAGE-A1 tumor-specific TCR or its antigen binding domain is a human TCR. In some embodiments, the MAGE-A1 tumor-specific TCR or its antigen binding domain is a chimeric TCR, such as a murinized TCR, for example a TCR comprising murine constant regions of the TCR α chain and β chain. In some embodiments, the MAGE-A1 tumor-specific TCR or its antigen binding domain comprises a human TCR variable region and a TCR constant region from a non-human species (such as a mouse).

[0083] In some embodiments, a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof is provided, comprising: a TCR α chain comprising an amino acid sequence having at least about 80% identity (e.g., at least about 85%, 90%, 95%, 98%, or any one of higher identity, or 100% identity) to any one of the amino acid sequences of SEQ ID NOs: 9, 23, and 37; and a TCR β chain comprising an amino acid sequence having at least about 80% identity (e.g., at least about 85%, 90%, 95%, 98%, or any one of higher identity, or 100% identity) to any one of the amino acid sequences of SEQ ID NOs: 12, 26, and 40.

[0084] Also provided is an isolated nucleic acid encoding the TCR alpha chain and / or the TCR beta chain of a tumor-specific TCR or its antigen-binding domain according to any one of the above-mentioned tumor-specific TCRs or its antigen-binding domains; a vector comprising the (etc.) isolated nucleic acid. In some embodiments, the isolated nucleic acid is a murinized nucleic acid sequence. In some embodiments, the isolated nucleic acid is a sequence-optimized murinized nucleic acid sequence.

[0085] III. Immune cells expressing MAGE-A1 tumor-specific TCR or its antigen-binding domain

[0086] One aspect of the present patent application provides an engineered immune cell comprising a tumor-specific TCR or its antigen-binding domain, an isolated nucleic acid, or a vector according to any one of the above-mentioned tumor-specific TCR or its antigen-binding domain.

[0087] The present application provides engineered immune cells expressing MAGE-A1 tumor-specific TCR or its antigen binding domain. In some embodiments, an effector cell (e.g., T cell) is provided, which presents any one of the MAGE-A1 tumor-specific TCR or its antigen binding domain described herein on its surface. In some embodiments, the effector cell comprises a nucleic acid encoding a MAGE-A1 tumor-specific TCR or its antigen binding domain, wherein the MAGE-A1 tumor-specific TCR or its antigen binding domain is expressed from the nucleic acid and localized on the effector cell surface. In some embodiments, the MAGE-A1 tumor-specific TCR or its antigen binding domain is exogenously expressed and combined with an effector cell. In some embodiments, the effector cell is a T cell. In some embodiments, the effector cell is selected from the group consisting of a cytotoxic T cell, a helper T cell, a natural killer T cell, and a suppressor T cell.

[0088] Cell modifications for disrupting gene expression include any such techniques known in the art, including, for example, RNA interference (e.g., siRNA, shRNA, miRNA), gene editing (e.g., gene knockout based on CRISPR or TALEN), etc. For example, in some embodiments, an effector cell (e.g., T cell) is provided, comprising a nucleic acid encoding any one of the MAGE-A1 tumor-specific TCR or its antigen binding domains described herein, wherein the MAGE-A1 tumor-specific TCR or its antigen binding domain is expressed from the nucleic acid and located on the surface of the effector cell. In some embodiments, an effector cell (e.g., T cell) is provided, comprising a first nucleic acid sequence encoding a first polypeptide chain of a MAGE-A1 tumor-specific TCR or its antigen binding domain and a second nucleic acid sequence encoding a second polypeptide chain of a MAGE-A1 tumor-specific TCR or its antigen binding domain. In some embodiments, the nucleic acid encoding the MAGE-A1 tumor-specific TCR or its antigen binding domain is located on a vector. In some embodiments, the first nucleic acid sequence is located on a first vector and the second nucleic acid sequence is located on a second vector. In some embodiments, the first and second nucleic acid sequences are located on the same vector. The vector can be selected from, for example, mammalian expression vectors and viral vectors (e.g., vectors derived from retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses). In some embodiments, the vector is integrated into the host genome of the effector cell. In some embodiments, the nucleic acid sequence encoding the MAGE-A1 tumor-specific TCR or its antigen-binding domain is under the control of a promoter. In some embodiments, the first nucleic acid sequence is under the control of a first promoter and the second nucleic acid sequence is under the control of a second promoter. In some embodiments, the first and second promoters have the same sequence. In some embodiments, the first and second promoters have different sequences. In some embodiments, the first and second nucleic acids are under the control of a single promoter. In some embodiments, the first, second, and / or single promoter is an inducible promoter. In some embodiments, the promoter is an inducible promoter. In some embodiments, the expression of the first polypeptide chain is approximately the same as the expression of the second polypeptide chain. In some embodiments, the expression of the first polypeptide chain is at least about two (e.g., at least about 2, 3, 4, 5, or more) times that of the expression of the second polypeptide chain. In some embodiments, expression of the first polypeptide chain is no more than about 1 / 2 (eg, no more than about any of 1 / 2, 1 / 3, 1 / 4, 1 / 5, or less) of the expression of the second polypeptide chain.

[0089] The expression of MAGE-1 tumor-specific TCR or its antigen binding domain can be determined by mRNA or protein levels. The expression level of mRNA can be determined by measuring the amount of mRNA transcribed from nucleic acid using various well-known methods, including Northern immunoblotting, quantitative RT-PCR, microarray analysis, etc. Protein expression levels can be measured by known methods, including immunocytochemical staining, enzyme-linked immunosorbent assay (ELISA), protein immunoblot analysis, luminescence analysis, mass spectrometry, high performance liquid chromatography, high pressure liquid chromatography-tandem mass spectrometry, etc.

[0090] In some embodiments, a MAGE-A1 tumor-specific TCR or antigen-binding domain thereof effector cell (e.g., T cell) is provided, which expresses on its surface any one of the MAGE-A1 tumor-specific TCR or antigen-binding domain thereof described herein, wherein the MAGE-A1 tumor-specific TCR or antigen-binding domain thereof effector cell comprises a host genome-integrated mammalian expression vector and a viral vector (e.g., a vector derived from a retrovirus, adenovirus, adeno-associated virus, herpes virus, and lentivirus), which comprises a first nucleic acid sequence encoding a first polypeptide chain of the MAGE-A1 tumor-specific TCR or antigen-binding domain thereof and a second nucleic acid sequence encoding a second polypeptide chain of the MAGE-A1 tumor-specific TCR or antigen-binding domain thereof. In some embodiments, there is a promoter operably linked to the 5' end of the first nucleic acid sequence, and there is a nucleic acid linker selected from an internal ribosome entry site (IRES) and a nucleic acid encoding a self-cleaving 2A peptide (e.g., P2A, T2A, E2A, or F2A) to connect the 3' end of the first nucleic acid sequence to the 5' end of the second nucleic acid sequence, wherein the first nucleic acid sequence and the second nucleic acid sequence are transcribed as a single RNA under the control of the promoter. In some embodiments, there is a promoter operably linked to the 5' end of the second nucleic acid sequence, and there is a nucleic acid linker selected from an internal ribosome entry site (IRES) and a nucleic acid encoding a self-cleaving 2A peptide (e.g., P2A, T2A, E2A, or F2A) to connect the 3' end of the second nucleic acid sequence to the 5' end of the first nucleic acid sequence, wherein the first nucleic acid sequence and the second nucleic acid sequence are transcribed as a single RNA under the control of the promoter. In some embodiments, the 2A peptide is P2A. In some embodiments, the promoter is an inducible promoter. In some embodiments, the effector cells are selected from the group consisting of cytotoxic T cells, helper T cells, natural killer T cells, and suppressor T cells.

[0091] In some embodiments, an effector cell (e.g., T cell) expressing a MAGE-A1 tumor-specific TCR on its surface is provided, comprising a) a first nucleic acid sequence encoding a first polypeptide chain, the first polypeptide chain comprising an amino acid sequence of SEQ ID NO: 9 and b) a second nucleic acid sequence encoding a second polypeptide chain, the second polypeptide chain comprising an amino acid sequence of SEQ ID NO: 12; and / or c) a first nucleic acid sequence encoding a first polypeptide chain, the first polypeptide chain comprising an amino acid sequence of SEQ ID NO: 23 and d) a second nucleic acid sequence encoding a second polypeptide chain, the second polypeptide chain comprising an amino acid sequence of SEQ ID NO: 26; and / or e) a first nucleic acid sequence encoding a first polypeptide chain, the first polypeptide chain comprising an amino acid sequence of SEQ ID NO: 37 and f) a second nucleic acid sequence encoding a second polypeptide chain, the second polypeptide chain comprising an amino acid sequence of SEQ ID NO: 40. In some embodiments, the effector cell expressing a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof further comprises a P2A nucleic acid sequence encoding SEQ ID NOs: 13, 27, 41. In some embodiments, an effector cell (eg, T cell) expressing a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof on its surface is provided, comprising a nucleic acid sequence encoding an amino acid sequence of one or more of SEQ ID NOs: 14, 28, 42.

[0092] In some embodiments, the target antigen of an effector cell (e.g., T cell) expressing a MAGE-A1 tumor-specific TCR or its antigen-binding domain on the surface is a MAGE-A1 peptide / MHC complex. In some embodiments, the MHC protein in the MAGE-A1 peptide / MHC complex is an MHC-I class protein. In some embodiments, the MHC-I class protein is HLA-A. In some embodiments, HLA-A is A*11:01. In some embodiments, the effector cell is a γδT cell. In some embodiments, the effector cell is an αβT cell. In some embodiments, the effector cell is selected from the group consisting of a cytotoxic T cell, a helper T cell, a natural killer T cell, and a suppressor T cell. In some embodiments, the target antigen of an effector cell (e.g., T cell) expressing a MAGE-A1 tumor-specific TCR or its antigen-binding domain on the surface is a MAGE-A1 96-104 Peptide / MHCI A*11:01 complex. In some embodiments, the immune cell is a T cell. In some embodiments, a pharmaceutical composition is provided, comprising an engineered immune cell according to any one of the engineered immune cells described above, and a pharmaceutically acceptable carrier.

[0093] IV. Preparation of effector cells expressing MAGE-A1 TCR or its antigen binding domain

[0094] In some embodiments, in one aspect, the present invention provides effector cells (e.g., lymphocytes, such as T cells) expressing MAGE-A1 tumor-specific TCR or its antigen binding domain. Exemplary preparation methods of effector cells (e.g., MAGE-A1 tumor-specific TCR effector cells, such as MAGE-A1 tumor-specific TCRT cells) expressing MAGE-A1 tumor-specific TCR or its antigen binding domain are provided herein. In some embodiments, MAGE-A1 tumor-specific TCR effector cells (e.g., MAGE-A1 tumor-specific TCRT cells) can be produced by introducing one or more nucleic acids (including, for example, lentiviral vectors) encoding MAGE-A1 tumor-specific TCR or its antigen binding domain (e.g., any one of the MAGE-A1 tumor-specific TCR or its antigen binding domain described herein) that specifically bind to a target antigen (e.g., a disease-associated antigen) into effector cells. The introduction of one or more nucleic acids into effector cells can be achieved using techniques known in the art, such as those described herein for nucleic acids. In some embodiments, the MAGE-A1 tumor-specific TCR effector cells of the invention (eg, MAGE-A1 tumor-specific TCRT cells) are capable of replicating in vivo, resulting in long-term persistence that can contribute to sustained control of diseases associated with expression of the target antigen (eg, cancer).

[0095] In some embodiments, the present invention relates to the use of lymphocyte infusion to administer genetically modified T cells to treat patients suffering from or at risk of developing diseases and / or conditions associated with the expression of a target antigen (also referred to herein as "target antigen positive" or "TA positive" diseases or conditions), including, for example, cancer, wherein the genetically modified T cells express any of the MAGE-A1 tumor-specific TCR or its antigen binding domains described herein. In some embodiments, autologous lymphocyte infusion is used in treatment. Autologous PBMCs are collected from patients in need of treatment and T cells are activated and expanded using methods described herein and known in the art, and then infused back into the patient. In some embodiments, a T cell expressing a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a target antigen according to any of the MAGE-A1 tumor-specific TCR or its antigen binding domains described herein (also referred to herein as a "MAGE-A1 tumor-specific TCRT cell") is provided. The MAGE-A1 tumor-specific TCRT cells of the present invention can undergo robust in vivo T cell expansion and can establish target antigen-specific memory cells that remain in the blood and bone marrow at high levels for a long time. In some embodiments, the MAGE-A1 tumor-specific TCRT cells of the present invention infused into a patient can eliminate cells presenting the target antigen in vivo in a patient with a target antigen-related disease, such as cancer cells presenting the target antigen. In some embodiments, the MAGE-A1 tumor-specific TCRT cells of the present invention infused into a patient can eliminate cells presenting the target antigen in vivo in a patient with a target antigen-related disease that is difficult to treat with at least one known therapy, such as cancer cells presenting the target antigen.

[0096] Before T cell expansion and gene modification, T cell sources are obtained from individuals. T cells can be obtained from a variety of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from infection sites, ascites, pleural effusion, spleen tissue and tumors. In some embodiments of the present invention, any number of T cell lines available in the art can be used. In some embodiments of the present invention, T cells can be obtained from using any number of techniques known to those skilled in the art (e.g., Ficoll TMIn some embodiments, cells from the circulating blood of an individual are obtained by apheresis. The apheresis product generally contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, erythrocytes, and platelets. In some embodiments, the cells collected by apheresis can be washed to remove the plasma portion and the cells are placed in an appropriate buffer or culture medium for subsequent processing steps. In some embodiments, cells are washed with phosphate buffered saline (PBS). In some embodiments, the washing solution lacks calcium and may lack magnesium or may lack many (if not all) divalent cations. As those skilled in the art will readily appreciate, the washing step can be achieved by methods known to those skilled in the art, such as by using semi-automatic "circulation" centrifugation (e.g., Cobe 2991 cell processor Baxter CytoMate or Haemonetics cell preserver 5) according to the manufacturer's instructions. After washing, the cells can be resuspended in a variety of biocompatible buffers, such as PBS without Ca2+, Mg2+, PlasmaLyteA, or other saline solutions with or without buffers. Alternatively, undesirable components of the hemophere sample can be removed and the cells resuspended directly in culture medium.

[0097] In some embodiments, by lysing red blood cells and, for example, by PERCOLL TM T cells are separated from peripheral blood lymphocytes by gradient centrifugation or by depletion of monocytes by counterflow centrifugal elutriation. Specific subpopulations of T cells (e.g., CD3+, CD28+, CD4+, CD8+, CD45RA+, and CD45RO+ T5 cells) can be further isolated by positive selection or negative selection techniques. For example, in some embodiments, by beads (e.g., 3×28) bound to anti-CD3 / anti-CD28 (i.e., 3×28) In some embodiments, the time period is about 30 minutes. In some embodiments, the time period is in the range of 30 minutes to 36 hours or longer (including all ranges between these values). In some embodiments, the time period is at least 1, 2, 3, 4, 5 or 6 hours. In some embodiments, the time period is 10 to 24 hours. In some embodiments, the incubation period is 24 hours. Regarding the separation of T cells from patients with leukemia, using a longer incubation time (e.g., 24 hours) can increase cell yield. In any case where there are fewer T cells compared to other cell types, a longer incubation time can be used to separate T cells, such as separating tumor infiltrating lymphocytes (TIL) from tumor tissue or immunocompromised individuals. In addition, using a longer incubation time can increase the capture efficiency of CD8+T cells. Therefore, by only shortening or extending the time that T cells are allowed to bind to CD3 / CD28 beads and / or by increasing or decreasing the ratio of beads to T cells, T cell subpopulations can be preferentially selected for or for the start of culture or other time points during the process. In addition, by increasing or decreasing the ratio of anti-CD3 and / or anti-CD28 antibodies on beads or other surfaces, T cell subpopulations can be preferentially selected for or for the start of culture or at other desired time points. Those skilled in the art will recognize that multiple selection rounds can also be used in the context of the present invention. In some embodiments, it may be necessary to perform a selection procedure and use "unselected" cells in the activation and amplification process. "Unselected" cells may also undergo other selection rounds.

[0098] Enrichment of T cell populations by negative selection can be achieved using a combination of antibodies for surface markers specific to negatively selected cells. One method is to sort and / or select cells via negative magnetic immunoadhesion or flow cytometry, which uses a mixture of monoclonal antibodies for cell surface markers present on negatively selected cells. For example, in order to enrich CD4+ cells by negative selection, a mixture of monoclonal antibodies typically includes antibodies for CD14, CD20, CD11b, CD16, HLA-DR, and CD8. In some embodiments, it may be necessary to enrich or positively select regulatory T cells that typically express CD4+, CD25+, CD62Lhi, GITR+, and FoxP3+. Alternatively, in some embodiments, T regulatory cells are exhausted by anti-CD25 binding beads or other similar selection methods.

[0099] In order to separate the desired cell population by positive selection or negative selection, the cell concentration and surface (e.g., particles, such as beads) can vary. In some embodiments, it may be necessary to significantly reduce the volume in which beads and cells are mixed together (i.e., increase the cell concentration) to ensure maximum contact between cells and beads. For example, in some embodiments, a concentration of about 2 billion cells / ml is used. In some embodiments, a concentration of about 1 billion cells / ml is used. In some embodiments, greater than about 100,000,000 cells / ml is used. In some embodiments, a cell concentration of any one of about 10,000,000, 15,000,000, 20,000,000, 25,000,000, 30,000,000, 35,000,000, 40,000,000, 45,000,000, or 50,000,000 cells / ml is used. In some embodiments, a cell concentration of any one of about 75,000,000, 80,000,000, 85,000,000, 90,000,000, 95,000,000 or 100,000,000 cells / ml is used. In some embodiments, a concentration of about 125,000,000 or about 150,000,000 cells / ml is used. Using high concentrations can lead to increased cell yields, cell activation and cell expansion. In addition, using high cell concentrations makes it more effective to capture cells (such as CD28 negative T cells) that may weakly express the target antigen of interest or to capture cells more effectively from samples (i.e., leukemia blood, tumor tissue, etc.) in which there are many tumor cells. Such cell colonies may have therapeutic value and are expected to be obtained. For example, using high cell concentrations allows more effective selection of CD8+T cells that generally have weaker CD28 expression.

[0100] In some embodiments of the present invention, T cells are obtained directly from patients after treatment. In this regard, it has been observed that after certain cancer treatments, especially after treatment with drugs that destroy the immune system, the quality of the T cells obtained can be optimal or their ability to be expanded in vitro is improved during the period when the patient will usually recover from the treatment shortly after treatment. Similarly, after the in vitro manipulation using the methods described herein, the enhanced transplantation and in vivo expansion of these cells can be in a preferred state. Therefore, the collection of blood cells (including T cells), dendritic cells, or other cells of the hematopoietic lineage during this recovery phase is encompassed within the context of the present invention. In addition, in some embodiments, movement (e.g., movement with GM-CSF) and regulation schemes can be used to establish conditions in individuals, wherein it is particularly appropriate to re-proliferate, recirculate, regenerate, and / or expand specific cell types during a limited time window after treatment. Illustrative cell types include T cells, B cells, dendritic cells, and other cells of the immune system. Whether before or after genetically modifying T cells to express the desired MAGE-A1 tumor-specific TCR or its antigen-binding domain, T cells can generally be activated and expanded using methods such as described in, for example, U.S. Patent Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005.

[0101] In general, the T cells of the present invention are amplified by contact with a surface to which are attached agents that stimulate CD3 / TCR complex-related signals and ligands that stimulate co-stimulatory molecules on the surface of T cells. Specifically, T cell populations can be stimulated, for example, by contact with anti-CD3 antibodies or their antigen-binding domains, or anti-CD2 antibodies fixed on the surface, or by contact with protein kinase C activators (e.g., bryostatin) bound to calcium ion carriers. In order to co-stimulate auxiliary molecules on the surface of T cells, ligands that bind to auxiliary molecules are used. For example, T cell populations can be contacted with anti-CD3 antibodies and anti-CD28 antibodies under conditions suitable for stimulating T cell proliferation. In order to stimulate the proliferation of CD4+T cells or CD8+T cells, anti-CD3 antibodies and anti-CD28 antibodies. Examples of anti-CD28 antibodies include 9.3, B-T3, XR-CD28 (DiaClone, France), other methods generally known in the art may be used (Berg et al., Transplant Proc. 30(8):3975-3977, 1998; Haanen et al., J. Exp. Med. 190(9):13191328, 1999; Garland et al., J. Immunol Meth. 227(1-2):53-63, 1999).

[0102] Genetic modification

[0103] In some embodiments, the MAGE-A1 tumor-specific TCR effector cells of the invention (e.g., MAGE-A1 tumor-specific TCRT cells) are generated by transducing effector cells (e.g., T cells prepared by the methods described herein) with a viral vector encoding a MAGE-A1 tumor-specific TCR as described herein. Viral vector delivery systems include DNA and RNA viruses that have free or integrated genomes after delivery to effector cells. For a review of gene therapy procedures, see Anderson, Science 256:808-813 (1992); Nabel and Feigner, TIBTECH 11:211-217 (1993); Mitani and Caskey, TIBTECH 11:162-166 (1993); Dillon, TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt, Biotechnology 6(10):1149-1154 (1988); Vigne, Restorative Neurology and Neuroscience 8:35-36 (1995); Kremer and Perricaudet, British Medical Bulletin 51(1):31-44 (1995); and Yu et al., Gene Therapy. Therapy1: 13-26 (1994). In some embodiments, the viral vector is a lentiviral vector, and the MAGE-A1 tumor-specific TCR effector cell comprises a lentiviral vector integrated into the MAGE-A1 tumor-specific TCR effector cell genome. In some embodiments, the MAGE-A1 tumor-specific TCR effector cell is a MAGE-A1 tumor-specific TCRT cell, which comprises a lentiviral vector integrated into its genome. In some embodiments, the MAGE-A1 tumor-specific TCR effector cell is a T cell modified to block or reduce the expression of one or both of the endogenous TCR chains. For example, in some embodiments, the MAGE-A1 tumor-specific TCR effector cell is an αβT cell modified to block or reduce the expression of TCRα and / or β chains, or the MAGE-A1 tumor-specific TCR effector cell is a γδT cell modified to block or reduce the expression of TCRγ and / or δ chains. Cellular modifications for disrupting gene expression include any such techniques known in the art, including, for example, RNA interference (e.g., siRNA, shRNA, miRNA), gene editing (e.g., CRISPR or TALEN-based gene knockout), and the like.

[0104] In some embodiments, the CRISPR / Cas system is used to generate MAGE-A1 tumor-specific TCRT cells with reduced expression of one or both of the endogenous TCR chains of T cells. For a review of the CRISPR / Cas system for gene editing, see, for example, Jian W and Marraffini LA, Annu. Rev. Microbiol. 69, 2015; Hsu PD et al., Cell, 157 (6): 1262-1278, 2014; and O'Connell MR et al., Nature 516: 263-266, 2014. In some embodiments, TALEN-based genome editing is used to generate MAGE-A1 tumor-specific TCRT cells with reduced expression of one or both of the endogenous TCR chains of T cells.

[0105] Enrichment

[0106] In some embodiments, a method for enriching a heterogeneous cell population according to any one of the MAGE-A1 tumor-specific TCR effector cells described herein is provided. A specific subpopulation of MAGE-A1 tumor-specific TCR effector cells (e.g., MAGE-A1 tumor-specific TCRT cells) that specifically bind to a target antigen can be enriched by a positive selection technique. For example, in some embodiments, MAGE-A1 tumor-specific TCR effector cells (e.g., T cells expressing MAGE-A1 tumor-specific TCR) are enriched by incubating with beads bound to the target antigen for a period sufficient to positively select the desired MAGE-A1 tumor-specific TCR effector cells. In some embodiments, the period is about 30 minutes. In some embodiments, the period is in the range of 30 minutes to 36 hours or longer (including all ranges between these values). In some embodiments, the period is at least 1, 2, 3, 4, 5, or 6 hours. In some embodiments, the period is 10 to 24 hours. In some embodiments, the incubation period is 24 hours. Regarding the isolation of MAGE-A1 tumor-specific TCR effector cells present at low levels in a heterogeneous cell population, using a longer incubation time (e.g., 24 hours) can increase cell yield. Longer incubation times can be used to isolate MAGE-A1 tumor-specific TCR effector cells in any situation where there are fewer MAGE-A1 tumor-specific TCR effector cells than other cell types.

[0107] Those skilled in the art will recognize that multiple selection rounds may also be used in the context of the present invention. In order to isolate the desired MAGE-A1 tumor-specific TCR effector cell population by positive selection or negative selection, the cell concentration and surface (e.g., particles, such as beads) may vary. In some embodiments, it may be necessary to significantly reduce the volume in which the beads and cells are mixed together (i.e., increase the cell concentration) to ensure maximum contact between the cells and the beads. For example, in some embodiments, a concentration of about 2 billion cells / ml is used. In some embodiments, a concentration of about 1 billion cells / ml is used. In some embodiments, greater than about 100 million cells / ml are used. In some embodiments, a cell concentration of about 10,000,000, 15,000,000, 20,000,000, 25,000,000, 30,000,000, 35,000,000, 40,000,000, 45,000,000, or 50,000,000 cells / ml is used. In some embodiments, a cell concentration of about 75,000,000, 80,000,000, 85,000,000, 90,000,000, 95,000,000, or 100,000,000 cells / ml is used. In some embodiments, a concentration of about 125,000,000 or about 150,000,000 cells / ml is used. The use of high concentrations can result in increased cell yield, cell activation, and cell expansion. In addition, the use of high cell concentrations allows for more efficient capture of MAGE-A1 tumor-specific TCR effector cells that may weakly express MAGE-A1 tumor-specific TCR or its antigen binding domain.

[0108] In some of any such embodiments described herein, enrichment results in minimal or substantially no MAGE-A1 tumor-specific TCR effector cell depletion. For example, in some embodiments, enrichment results in less than about 50% (e.g., less than about 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10% or 5%) of MAGE-A1 tumor-specific TCR effector cells being depleted. Effector cell depletion can be determined by any means known in the art, including any means described herein. In some of any such embodiments described herein, enrichment results in minimal or substantially no final differentiation of MAGE-A1 tumor-specific TCR effector cells. For example, in some embodiments, enrichment results in less than about 50% (e.g., less than about 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10% or 5%) of MAGE-A1 tumor-specific TCR effector cells being finally differentiated. Effector cell differentiation can be determined by any means known in the art, including any means described herein.

[0109] In some of any such embodiments described herein, the enrichment results in minimal or substantially no internalization of the MAGE-A1 tumor-specific TCR or its antigen-binding domain on the MAGE-A1 tumor-specific TCR effector cells. For example, in some embodiments, the enrichment results in less than about 50% (e.g., less than about 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%) of the MAGE-A1 tumor-specific TCR or its antigen-binding domain on the MAGE-A1 tumor-specific TCR effector cells being internalized. The internalization of the MAGE-A1 tumor-specific TCR or its antigen-binding domain on the MAGE-A1 tumor-specific TCR effector cells can be determined by any means known in the art, including any of the means described herein.

[0110] In some of any such embodiments described herein, the enrichment results in increased proliferation of MAGE-A1 tumor-specific TCR effector cells. For example, in some embodiments, the enrichment results in an increase in the number of MAGE-A1 tumor-specific TCR effector cells after enrichment by at least about 10% (e.g., at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 1000% or more). Therefore, in some embodiments, a method for enriching MAGE-A1 tumor-specific TCR effector cells expressing MAGE-A1 tumor-specific TCR or its antigen-binding domain that specifically binds to a target antigen in a heterogeneous cell population is provided, comprising: a) contacting the heterogeneous cell population with a ligand comprising the target antigen or one or more epitopes contained therein to form a complex comprising MAGE-A1 tumor-specific TCR effector cells bound to the ligand; and b) separating the complex from the heterogeneous cell population, thereby producing a cell population enriched with MAGE-A1 tumor-specific TCR effector cells. In some embodiments, the ligand is fixed to a solid support. In some embodiments, the solid support is a microparticle (e.g., a bead). In some embodiments, the solid support is a surface (e.g., the bottom of a well). In some embodiments, the ligand is labeled with a tag. In some embodiments, the tag is a fluorescent molecule, an affinity tag, or a magnetic tag. In some embodiments, the method further comprises eluting the MAGE-A1 tumor-specific TCR effector cells from the ligand and recovering the eluate.

[0111] In some embodiments, T cells can be enriched by screening CD3 and IFN-γ by FACS method. In some embodiments, T cells can be enriched by screening IFN-γ by ELISA method.

[0112] In some embodiments, the interaction occurs on the labeled ligand target (e.g., biotin-labeled ligand) in the solution. In some embodiments, the procedure involves one or more washing steps (elutriation) for removing nonspecific and non-responsive library members. In some embodiments, in order to purify the complex in the solution, the complex is captured by fixation or by centrifugation. In some embodiments, the affinity member is captured on a soluble biotin-labeled ligand, and then the affinity complex (affinity member and ligand) is fixed on avidin beads. In some embodiments, the solid carrier is a bead. In some embodiments, beads include, for example, magnetic beads (e.g., from Bangs Laboratories, Polysciences inc., Dynal Biotech, Miltenyi Biotech or Quantum Magnetic), non-magnetic beads (e.g., Pierce and Upstate technology), monodisperse beads (e.g., Dynal Biotech and Microparticle GmbH) and polydisperse beads (e.g., Chemagen). The use of magnetic beads is well described in the literature (Uhlen, M et al. (1994) Advances in Biomagnetic Separation, Bio Techniques press, 5 Westborough, MA). In some embodiments, affinity members are purified by positive selection. In some embodiments, affinity members are purified by negative selection to remove undesirable library members. In some embodiments, affinity members are purified by positive and negative selection steps.

[0113] In general, the techniques for preparing the library constructs will be based on known genetic engineering techniques. In this regard, the nucleic acid sequence encoding the MAGE-A1 tumor-specific TCR or its antigen binding domain to be expressed in the library is incorporated into an expression vector suitable for the type of expression system to be used. Suitable expression vectors for presentation in cells such as CD3+ cells are well known and described in the art. For example, in some embodiments, the expression vector is a viral vector, such as a lentiviral vector.

[0114] In some embodiments, a nucleic acid library is provided, comprising a sequence encoding a plurality of MAGE-A1 tumor-specific TCRs or antigen-binding domains thereof according to any one of the embodiments described herein. In some embodiments, the nucleic acid library comprises a viral vector encoding a plurality of MAGE-A1 tumor-specific TCRs or antigen-binding domains thereof. In some embodiments, the viral vector is a lentiviral vector. In some embodiments, a method for screening a sequence encoding a MAGE-A1 tumor-specific TCR or antigen-binding domain thereof specific to a target antigen in a nucleic acid library according to any one of the embodiments described herein is provided, comprising: a) introducing a nucleic acid library into a plurality of cells so that the MAGE-A1 tumor-specific TCR or antigen-binding domain thereof is expressed on the surface of a plurality of cells; b) incubating a plurality of cells with a ligand comprising a target antigen or one or more epitopes contained therein; c) collecting cells bound to the ligand; and d) isolating the sequence encoding the MAGE-A1 tumor-specific TCR or antigen-binding domain thereof from the cells collected in step c), thereby identifying a MAGE-A1 tumor-specific TCR or antigen-binding domain thereof specific to the target antigen. In some embodiments, the method further comprises one or more washing steps. In some embodiments, one or more washing steps are performed between steps b) and c). In some embodiments, a plurality of cells are a plurality of CD3+ cells. In some embodiments, the ligand is fixed to a solid support. In some embodiments, the solid support is a bead. In some embodiments, collecting cells bound to the ligand comprises eluting cells from the ligand bound to the solid support and collecting the eluate. In some embodiments, the ligand is labeled. In some embodiments, the label is a fluorescent molecule, an affinity label, or a magnetic label. In some embodiments, collecting cells bound to the ligand comprises separating a complex comprising the cell and the labeled ligand. In some embodiments, the cell is dissociated from the complex.

[0115] MHC proteins

[0116] Human leukocyte antigen (HLA) genes are human forms of MHC genes. The three main MHC class I proteins involved in antigen presentation in humans are HLA-A, HLA-B, and HLA-C. In some embodiments, a complex of a peptide of a related antigen (e.g., a tumor-associated or virus-encoded antigen) and an MHC class I protein. In some embodiments, in some embodiments, the MHC class I protein is HLA-A. Peptides suitable for generating antigen binding modules can be determined, for example, based on the presence of HLA (e.g., HLA-DRA*01:01) binding motifs and cleavage sites for proteasomes and immunoproteasomes, using computer prediction models known to those skilled in the art. For predicting MHC binding sites, such models include, but are not limited to, ProPred1 (described in more detail in Singh and Raghava, ProPred: prediction 20 of HLA-DR binding sites. BIOINFORMATICS 17(12):1236-1237, 2001) and SYFPEITHI (see Schuler et al. SYFPEITHI, Database for Searching and T-Cell Epitope Prediction. Immunoinformatics Methods in Molecular Biology, Vol. 409(1):75-93, 2007).

[0117] Once suitable peptides are identified, peptide synthesis can be completed according to schemes known to those skilled in the art. The peptide of the present invention can be synthesized directly in solution or on a solid support according to known peptide synthesis techniques due to its relatively small size. Various automatic synthesizers are commercially available and can be used according to known protocols. Synthetic peptides have become recognized procedures for large-scale manufacture of synthetic peptides in the solution phase, and therefore are suitable alternative methods for preparing the peptides of the present invention (see, for example, Solid Phase Peptide Synthesis, John Morrow Stewart and Martin et al. Application of Almez-mediated Amidation Reactions to Solution Phase Peptide Synthesis, Tetrahedron Letters Vol. 39, pp. 1517-1520, 1998).

[0118] In some embodiments, the MHC protein in the MAGE-A1 peptide / MHC complex is an MHC-I class protein. In some embodiments, the MHC-I class protein is HLA-A. In some embodiments, the target antigen of the effector cell (e.g., T cell) expressing a MAGE-A1 tumor-specific TCR or its antigen-binding domain on its surface is MAGE-A1. 96-104 Peptide / MHCI A*11:01 complex.

[0119] Variants

[0120] In some embodiments, amino acid sequence variants of the MAGE-A1 TCR or its antigen binding domain provided herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the MAGE-A1 TCR or its antigen binding domain. Amino acid sequence variants of the MAGE-A1 TCR or its antigen binding domain may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the MAGE-A1 TCR or its antigen binding domain or by peptide synthesis. Such modifications include, for example, deletion and / or insertion and / or substitution of residues within the amino acid sequence. Any combination of deletion, insertion and substitution may be performed to obtain the final construct, subject to the proviso that the final construct has the desired characteristics, such as antigen binding. In some embodiments, a MAGE-A1 TCR or its antigen binding domain variant having one or more amino acid substitutions is provided. Amino acid substitutions may be introduced into the relevant MAGE-A1 TCR or its antigen binding domain and the product may be screened for the desired activity, such as retained / improved antigen binding or reduced immunogenicity.

[0121] Conservative substitutions are shown in Table 2 below.

[0122] Amino acids can be grouped into different categories based on common side chain properties:

[0123] Hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile;

[0124] Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;

[0125] Acidic: Asp, Glu;

[0126] Basic: His, Lys, Arg;

[0127] Residues that affect chain orientation: Gly, Pro;

[0128] Aromatic: Trp, Tyr, Phe.

[0129] Non-conservative substitutions will necessarily involve exchanging a member of one of these classes for another class. Exemplary substitution variants are affinity matured antibody portions, which can be conveniently generated, for example, using affinity maturation techniques based on phage display. Briefly, one or more CDR residues are mutated and the variant antibody portions are displayed on phage and screened for a particular biological activity (e.g., binding affinity).

[0130] Table 2: Conservative substitutions

[0131] Original residue Exemplary substitutions Better replacement Ala(A) Val; Leu; Ile Val Arg(R) Lys; Gln; Asn Lys Asn(N) Gln; His; Asp, Lys; Arg Gln Asp(D) Glu; Asn Glu Cys(C) Ser; Ala Ser Gln(Q) Asn;Glu Asn Glu(E) Asp; Gln Asp Gly(G) Ala Ala His(H) Asn; Gln; Lys; Arg Arg Ile(I) Leu; Val; Met: Ala; Phe: norleucine Leu Leu(L) nor-leucine; Ile; Val; Met; Ala; Phe Ile Lys(K) Arg; Gln; Asn Arg Met(M) Leu; Phe; Ile Leu Phe(F) Trp; Leu; Val; Ile; Ala; Tyr Tyr Pro(P) Ala Ala Ser(S) Thr Thr Thr(T) Val; Ser Ser Trp(W) Tyr; Phe Tyr Tyr(Y) Trp; Phe; Thr; Ser Phe Val(V) Ile; Leu; Met; Phe; Ala; nor-leucine Leu

[0132] Briefly, one or more CDR residues are mutated and the variant portions displayed on phage and screened for a particular biological activity (eg, binding affinity).

[0133] Changes (e.g., substitutions) can be made in the MAGE-A1 TCR or its antigen binding domain to, for example, improve affinity. Affinity maturation achieved by construction of a secondary library and reselection from the secondary library has been described, for example, in Hoogenboom et al. Methods in Molecular Biology 178: 1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, (2001)). In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then generated. The library is then screened to identify any TCR or antigen binding domain partial variants having the desired affinity. CDR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. Specifically, CDR3 is typically targeted.

[0134] In some embodiments, substitutions, insertions or deletions may occur within one or more CDRs, as long as these changes do not substantially reduce the ability of the antibody moiety to bind to the antigen. For example, conservative changes (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in a TCR or its antigen-binding domain. In certain embodiments of the variant TCR or its antigen-binding domain provided above, each CDR is unchanged or contains no more than one, two or three amino acid substitutions.

[0135] A useful method for identifying residues or regions of the antibody portion that can be targeted for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham and Wells (1989) Science, 244: 1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the TCR or its antigen binding domain with the MHC antigen complex is affected. Additional substitutions can be introduced at amino acid positions that show functional sensitivity to the initial substitutions. Alternatively or additionally, a crystal structure of the antigen-MHC-TCR portion complex can be determined to identify contact points between the antibody portion and the antigen. Such contact residues and neighboring residues can be targeted or excluded as substitution candidates. Variants can be screened to determine whether they contain the desired properties.

[0136] Amino acid sequence insertions include amino and / or carboxyl terminal fusions ranging in length from one residue to polypeptides containing one hundred or more residues, as well as intrasequence insertions with single or multiple amino acid residues. Examples of terminal insertions include TCR portions with an N-terminal methionyl residue. Other insertion variants of the TCR portion include fusions of the N-terminus or C-terminus of the TCR portion with an enzyme (e.g., for ADEPT) or a polypeptide that extends the serum half-life of the antibody portion.

[0137] derivative

[0138] In some embodiments, the MAGE-A1 tumor-specific TCR or its antigen-binding domain according to any of the MAGE-A1 tumor-specific TCRs or their antigen-binding domains described herein may be further modified to contain additional non-protein moieties known in the art and readily available. Moieties suitable for derivatization of the MAGE-A1 tumor-specific TCR or its antigen-binding domain include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, poly-5-dextrose, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers) and polydextrose or poly(n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polyoxypropylene / ethylene oxide copolymers, polyoxyethylene polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have manufacturing advantages due to its stability in water. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to the MAGE-A1 tumor-specific TCR or its antigen-binding domain may vary, and if more than one polymer is attached, they may be the same or different molecules. In general, the number and / or type of polymers used for derivatization may be determined based on considerations including, but not limited to, the specific property or function of the MAGE-A1 tumor-specific TCR or its antigen-binding domain to be improved, whether the MAGE-A1 tumor-specific TCR or its antigen-binding domain derivative will be used for therapy under defined conditions, and the like.

[0139] In some embodiments, a conjugate of a MAGE-A1 tumor-specific TCR or an antigen binding domain thereof with a non-protein moiety that can be selectively heated by exposure to radiation is provided. In some embodiments, the non-protein moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)). The radiation can be of any wavelength and includes, but is not limited to, wavelengths that do not damage normal cells but heat the non-protein moiety to a temperature that kills cells proximal to the MAGE-A1 tumor-specific TCR-non-protein moiety.

[0140] V. Pharmaceutical Compositions

[0141] Also provided herein is a composition (e.g., a pharmaceutical composition, also referred to herein as a formulation) comprising a MAGE-A1 tumor-specific TCR or its antigen binding domain according to any one of the embodiments described herein, a nucleic acid encoding a MAGE-A1 tumor-specific TCR or its antigen binding domain according to any one of the embodiments described herein, or a MAGE-A1 tumor-specific TCR effector cell according to any one of the embodiments described herein. In some embodiments, the composition is a MAGE-A1 tumor-specific TCR effector cell composition (e.g., a pharmaceutical composition) comprising an effector cell (e.g., T cell) presenting a MAGE-A1 tumor-specific TCR or its antigen binding domain according to any one of the MAGE-A1 tumor-specific TCR or its antigen binding domain described herein on the surface. In some embodiments, the MAGE-A1 tumor-specific TCR effector cell composition is a pharmaceutical composition. The composition may comprise a homogeneous cell population or a heterogeneous cell population, wherein the homogeneous cell population comprises MAGE-A1 tumor-specific TCR effector cells of the same cell type and expressing the same MAGE-A1 tumor-specific TCR or its antigen-binding domain, and the heterogeneous cell population comprises a plurality of MAGE-A1 tumor-specific TCR effector cells comprising different cell types and / or expressing different MAGE-A1 tumor-specific TCR or its antigen-binding domain. The composition may further comprise cells that are not MAGE-A1 tumor-specific TCR effector cells. Therefore, in some embodiments, a MAGE-A1 tumor-specific TCR effector cell composition is provided, which comprises a homogeneous cell population of MAGE-A1 tumor-specific TCR effector cells (e.g., MAGE-A1 tumor-specific TCRT cells) of the same cell type and expressing the same MAGE-A1 tumor-specific TCR. In some embodiments, the MAGE-A1 tumor-specific TCR effector cells are T cells. In some embodiments, the MAGE-A1 tumor-specific TCR effector cells are selected from the group consisting of cytotoxic T cells, helper T cells, natural killer T cells, and suppressor T cells. In some embodiments, the MAGE-A1 tumor-specific TCR effector cell composition is a pharmaceutical composition.

[0142] In some embodiments, a MAGE-A1 tumor-specific TCR effector cell composition is provided, which comprises a heterogeneous cell population, the heterogeneous cell population comprises a plurality of MAGE-A1 tumor-specific TCR effector cell populations, and the MAGE-A1 tumor-specific TCR effector cell population comprises different cell types and / or MAGE-A1 tumor-specific TCRs expressing different MAGE-A1 tumor-specific TCRs or their antigen-binding domains. In some embodiments, the MAGE-A1 tumor-specific TCR effector cells are T cells. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population has a cell type selected from cytotoxic T cells, helper T cells, natural killer T cells, and suppressor T cells. In some embodiments, all MAGE-A1 tumor-specific TCR effector cells in the composition have the same cell type (e.g., all MAGE-A1 tumor-specific TCR effector cells are cytotoxic T cells). In some embodiments, at least one MAGE-A1 tumor-specific TCR effector cell population has a cell type different from other MAGE-A1 tumor-specific TCR effector cell populations (e.g., one MAGE-A1 tumor-specific TCR effector cell population is composed of cytotoxic T cells and other MAGE-A1 tumor-specific TCR effector cell populations are composed of natural killer T cells). In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population expresses the same MAGE-A1 tumor-specific TCR or its antigen binding domain. In some embodiments, at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that is different from other MAGE-A1 tumor-specific TCR effector cell populations. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that is different from other MAGE-A1 tumor-specific TCR effector cell populations. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to the same target antigen. In some embodiments, at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a target antigen different from that of other MAGE-A1 tumor-specific TCR effector cell populations (e.g., one MAGE-A1 tumor-specific TCR effector cell population specifically binds to a pMHC complex and other MAGE-A1 tumor-specific TCR effector cell populations specifically bind to a cell surface receptor).In some embodiments, wherein at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a different target antigen, each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a target antigen associated with the same disease or disorder (e.g., each of the target antigens is associated with cancer, such as breast cancer). In some embodiments, the MAGE-A1 tumor-specific TCR effector cell composition is a pharmaceutical composition.

[0143] Thus, in some embodiments, a MAGE-A1 tumor-specific TCR effector cell composition is provided, comprising a plurality of MAGE-A1 tumor-specific TCR effector cell populations according to any one of the embodiments described herein, wherein all MAGE-A1 tumor-specific TCR effector cells in the composition have the same cell type (e.g., all MAGE-A1 tumor-specific TCR effector cells are cytotoxic T cells), and wherein each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen-binding domain that is different from other MAGE-A1 tumor-specific TCR effector cell populations. In some embodiments, the MAGE-A1 tumor-specific TCR effector cells are T cells. In some embodiments, the MAGE-A1 tumor-specific TCR effector cells are selected from the group consisting of cytotoxic T cells, helper T cells, natural killer T cells, and suppressor T cells. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen-binding domain that specifically binds to the same target antigen. In some embodiments, at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a target antigen that is different from other MAGE-A1 tumor-specific TCR effector cell populations (e.g., one MAGE-A1 tumor-specific TCR effector cell population specifically binds to a pMHC complex and other MAGE-A1 tumor-specific TCR effector cell populations specifically bind to a cell surface receptor). In some embodiments, where at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a different target antigen, each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a target antigen associated with the same disease or disorder (e.g., each of the target antigens is associated with cancer, such as breast cancer). In some embodiments, the MAGE-A1 tumor-specific TCR effector cell composition is a pharmaceutical composition.

[0144] In some embodiments, a composition is provided, comprising a plurality of MAGE-A1 tumor-specific TCR effector cell populations according to any one of the embodiments described herein, wherein at least one MAGE-A1 tumor-specific TCR effector cell population has a cell type different from other MAGE-A1 tumor-specific TCR effector cell populations. In some embodiments, all MAGE-A1 tumor-specific TCR effector cell populations have different cell types. In some embodiments, MAGE-A1 tumor-specific TCR effector cells are T cells. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population has a cell type selected from cytotoxic T cells, helper T cells, natural killer T cells, and suppressor T cells. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population expresses the same MAGE-A1 tumor-specific TCR or its antigen-binding domain. In some embodiments, at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen-binding domain that is different from other MAGE-A1 tumor-specific TCR effector cell populations. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that is different from other MAGE-A1 tumor-specific TCR effector cell populations. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to the same target antigen. In some embodiments, at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a target antigen that is different from other MAGE-A1 tumor-specific TCR effector cell populations (e.g., one MAGE-A1 tumor-specific TCR effector cell population specifically binds to a pMHC complex and other MAGE-A1 tumor-specific TCR effector cell populations specifically bind to cell surface receptors). In some embodiments, wherein at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a different target antigen, each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a target antigen associated with the same disease or disorder (e.g., each of the target antigens is associated with cancer, such as breast cancer). In some embodiments, the MAGE-A1 tumor-specific TCR effector cell composition is a pharmaceutical composition.

[0145] At various points during the preparation of the composition, it may be necessary or desirable to cryopreserve the cells. The terms "frozen" or "freezing" and "cryopreserved" or "cryopreserving" are used interchangeably. Freezing includes freeze drying.

[0146] As those skilled in the art will appreciate, freezing cells can be damaging (see Mazur, P., 1977, Cryobiology 14: 251-272), but there are a number of procedures available to prevent such damage. For example, damage can be avoided by (a) using cryoprotectants, (b) controlling the freezing rate, and / or (c) storing at sufficiently low temperatures to minimize degradation responses. Exemplary cryoprotectants include dimethyl sulfoxide (DMSO) (Lovelock and Bishop, 1959, Nature 183: 1394-1395; Ashwood-Smith, 1961, Nature 190: 1204-1205), glycerol, polyvinylpyrrolidone (Rinfret, 1960, Ann. NY Acad. Sci. 85: 576), polyethylene glycol (Sloviter and Ravdin, 1962, Nature 196: 548), albumin, polydextrose, sucrose, ethylene glycol, i-erythritol, D-ribitol, D-mannitol (Rowe et al., 1962, Fed. Proc. 21: 157), D-sorbitol, i-inositol, D-lactose, choline chloride (Bender et al., 1960, J. Appl. Physiol. 15: 520), amino acids (Phan The Tran and Bender, 1960, Exp. Cell Res. 20: 651), methanol, acetamide, glycerol monoacetate (Lovelock, 1954, Bio Chem. J. 56: 265) and inorganic salts (Phan The Tran and Bender, 1960, Proc. Soc. Exp. Biol. Med. 104: 388; Phan The Tran and Bender, 1961, Radiobiology, Proceedings of the Third Australian Conference on Radiobiology, llbery ed., Butterworth, London, p. 59). In a specific embodiment, DMSO can be used. Adding plasma (e.g., to a concentration of 20-25%) can enhance the protective effect of DMSO. After adding DMSO, cells can be kept at 0°C until frozen, because 1% DMSO concentration can be toxic at temperatures above 4°C.

[0147] In the cryopreservation of cells, a slow controlled cooling rate can be critical and different cryoprotectants (Rapatz et al., 1968, Cryobiology 5(1):18-25) and different cell types have different optimal cooling rates (for the effect of cooling rate on the survival rate of stem cells and on their transplantation potential, see, for example, Rowe and Rinfret, 1962, Blood 20:636; Rowe, 5 1966, Cryo biology 3(1):12-18; Lewis et al., 1967, Transfusion 7(1):17-32; and Mazur, 1970, Science 168:939-949). The heat of the melting stage of water into ice should be very small. The cooling program can be performed by using, for example, a programmable freezing device or a methanol bath program. The programmable freezing device allows the determination of the optimal cooling rate and facilitates standard reproducible cooling.

[0148] In a particular embodiment, DMSO-treated cells can be pre-cooled on ice and transferred to a tray containing refrigerated methanol, which in turn is placed in a mechanical refrigerator (e.g., Harris or Revco) at -80°C. Thermocouple measurements of the methanol bath and samples indicate that a cooling rate of 1°C to 3°C / minute may be preferred. After at least two hours, the sample can reach a temperature of -80°C and can be placed directly into liquid nitrogen (-196°C). After thorough freezing, the cells can be quickly transferred to a long-term cryogenic storage container.

[0149] In a preferred embodiment, samples can be cryogenically stored in liquid nitrogen (-196°C or) vapor (-1°C). The availability of high-efficiency liquid nitrogen freezers facilitates such storage. Additional considerations and procedures for manipulation, cryopreservation, and long-term storage of cells can be found in the following exemplary references: U.S. Pat. Nos. 4,199,022, 3,753,357, and 4,559,298; Gorin, 1986, Clinics In Haematology 15(1):19-48 Bone-Marrow Conservation, Culture and Transplantation, Proceedings of a Panel, Moscow, July 22-26, 1968, International Atomic Energy Agency, Vienna, pp. 107-186; Livesey and Linner, 1987, Nature 327:255; Linner et al., 1986, J. HistoChem. CytoChem. 34(9):1123-1135; Simione, 1992, J. Parenter. Sci. TeChnol. 46(6):226-32.

[0150] After cryopreservation, the frozen cells can be thawed for use according to methods known to those skilled in the art. The frozen cells are preferably thawed quickly and refrigerated immediately after thawing. In a specific embodiment, the vial containing the frozen cells can be immersed in a warm water bath up to its neck; gentle rotation will ensure that the cell suspension is mixed as it thaws and improve heat transfer from the warm water to the internal ice. Once the ice is completely melted, the vial can be immediately placed on ice.

[0151] In certain embodiments, methods for preventing cell aggregation may be used during thawing. Exemplary methods include: adding deoxyribonuclease (Spitzer et al., 1980, Cancer 45: 3075-3085), low molecular weight polydextrose and citrate, hydroxyethyl starch (Stiff et al., 1983, Cryobiology 20: 17-24), etc. before and / or after freezing. As is known to those skilled in the art, if a cryoprotectant toxic to humans is used, it should be removed before therapeutic use. DMSO is not severely toxic.

[0152] Exemplary carriers and modes of cell administration are described in U.S. Patent Publication No. 2010 / 0183564, pp. 14-15. Other pharmaceutical carriers are described in Remington: The Science and Practice of Pharmacy, 21st edition, David B. Troy, ed., Lippicott Williams & Wilkins (2005).

[0153] In certain embodiments, cells can be collected from the culture medium, washed and concentrated in a carrier to a therapeutically effective amount. Exemplary carriers include saline, buffered saline, saline, water, Hanks' solution, Ringer's solution, Nonnosol-R (Abbott Labs), Plasma-Lyte A(R) (Baxter Laboratories, Inc., Morton Grove, IL), glycerol, ethanol, and combinations thereof.

[0154] In certain embodiments, the carrier can be supplemented with human serum albumin (HSA) or other human serum components or fetal bovine serum. In certain embodiments, the infusion carrier includes buffered saline containing 5% HSA or dextrose. Other isotonic agents include polyhydroxy sugar alcohols, including triols or higher sugar alcohols, such as glycerol, erythritol, arabitol, xylitol, sorbitol or mannitol.

[0155] The carrier may include a buffer, such as a citrate buffer, a succinate buffer, a tartrate buffer, a fumarate buffer, a gluconate buffer, an oxalate buffer, a lactate buffer, an acetate buffer, a phosphate buffer, a histidine buffer, and / or a trimethylamine buffer.

[0156] Stabilizers refer to a broad class of excipients whose functions can range from bulking agents to additives that help prevent cells from adhering to the walls of the container. Typical stabilizers may include polyhydroxy sugar alcohols; amino acids such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid and threonine; organic sugars or sugar alcohols such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myo-inositol, galactitol, glycerol and cyclic alcohols such as inositol; PEG; amino acid polymers; sulfur-containing reducing agents such as urea, glutathione, lipoic acid, sodium thioglycolate, thioglycerol, α-monothioglycerol and sodium thiosulfate; low molecular weight polypeptides (i.e., <10 residues); proteins such as HSA, bovine serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; monosaccharides such as xylose, mannose, fructose and glucose; disaccharides such as lactose, maltose and sucrose; trisaccharides such as raffinose; and polysaccharides such as polydextrose.

[0157] Where necessary or advantageous, the composition may include a local anesthetic such as lidocaine to ease pain at the site of the injection.

[0158] Exemplary preservatives include phenol, benzyl alcohol, m-cresol, methylparaben, propylparaben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides, hexahydroxyquaternary ammonium chloride, alkylparabens (e.g., methyl or propylparaben), catechol, resorcinol, cyclohexanol, and 3-pentanol.

[0159] The therapeutically effective amount of cells in the composition may be greater than 10 2 cells, greater than 10 3 cells, greater than 10 4 cells, greater than 10 5 cells, greater than 10 6 cells, greater than 10 7 cells, greater than 10 8 cells, greater than 10 9 cells, greater than 10 10 cells or more than 10 11 In the compositions and formulations disclosed herein, the volume of the cells is generally one liter or less, 500 ml or less, 250 ml or less, or 100 ml or less. Thus, the cell density used is generally greater than 10 4 cells / mL, 10 7 cells / mL or 10 8 cells / ml.

[0160] Also provided herein is a MAGE-A1 tumor-specific TCR nucleic acid composition (e.g., a pharmaceutical composition, also referred to herein as a formulation), comprising any of the nucleic acids encoding the MAGE-A1 tumor-specific TCR or its antigen-binding domain described herein. In some embodiments, the MAGE-A1 tumor-specific TCR nucleic acid composition is a pharmaceutical composition. In some embodiments, the MAGE-A1 tumor-specific TCR nucleic acid composition further comprises any of the following: an isotonic agent, an excipient, a diluent, a thickener, a stabilizer, a buffer and / or a preservative; and / or an aqueous vehicle, such as purified water, a sugar solution, a buffer solution, a physiological saline solution, a polymer aqueous solution, or water without ribonucleases. The amount of such additives and aqueous vehicles to be added can be appropriately selected according to the form of use of the MAGE-A1 tumor-specific TCR nucleic acid composition.

[0161] The compositions and formulations disclosed herein can be prepared for administration by, for example, injection, infusion, perfusion or lavage. The compositions and formulations can be further formulated for intramedullary, intravenous, intradermal, intraarterial, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesicular and / or subcutaneous injection.

[0162] Formulations for in vivo administration must be sterile. This requirement is easily achieved, for example, by filtration through a sterile filtration membrane. Treatment methods using MAGE-A1 tumor-specific TCRs or antigen-binding domains thereof The MAGE-A1 tumor-specific TCRs or antigen-binding domains thereof and / or compositions of the present invention may be administered to an individual (e.g., a mammal, such as a human) to treat diseases and / or conditions associated with target antigen (TA) expression (also referred to herein as "target antigen-positive" or "TA-positive" diseases or conditions), including, for example, cancer. Therefore, in some embodiments, the present application provides a method for treating a target antigen-positive disease (e.g., cancer) in an individual, comprising administering to the individual an effective amount of a composition (e.g., a pharmaceutical composition), the composition comprising, for example, any of the MAGE-A1 tumor-specific TCRs or antigen-binding domains thereof described herein.

[0163] In some embodiments, the composition further comprises a cell (e.g., an effector cell) associated with a MAGE-A1 tumor-specific TCR or its antigen binding domain. In some embodiments, the cancer is selected from, for example, adrenocortical carcinoma, bladder cancer, breast cancer, cervical cancer, bile duct cancer, colorectal cancer, esophageal cancer, glioblastoma, glioma, liver cancer, head and neck cancer, kidney cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, pancreatic cancer, pheochromocytoma, plasmacytoma, neuroblastoma, ovarian cancer, prostate cancer, sarcoma, gastric cancer, uterine cancer, and thyroid cancer.

[0164] VI. Treatment Methods

[0165] In some embodiments, a method of treating a target antigen-associated disease (e.g., cancer) in a subject in need thereof is provided, comprising administering to the subject an effective amount of a composition comprising a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof according to any one described herein, or a nucleic acid encoding a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof according to any one described herein, or an effector cell (e.g., a T cell or a natural killer cell) presenting a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof (e.g., a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof) on its surface. In some embodiments, the composition comprises a) a first nucleic acid sequence encoding a first polypeptide chain, the first polypeptide chain comprising an amino acid sequence of SEQ ID NO: 9 and b) a second nucleic acid sequence encoding a second polypeptide chain, the second polypeptide chain comprising an amino acid sequence of SEQ ID NO: 12; and / or c) a first nucleic acid sequence encoding a first polypeptide chain, the first polypeptide chain comprising an amino acid sequence of SEQ ID NO: 23 and d) a second nucleic acid sequence encoding a second polypeptide chain, the second polypeptide chain comprising an amino acid sequence of SEQ ID NO: 26; and / or e) a first nucleic acid sequence encoding a first polypeptide chain, the first polypeptide chain comprising an amino acid sequence of SEQ ID NO: 37 and f) a second nucleic acid sequence encoding a second polypeptide chain, the second polypeptide chain comprising an amino acid sequence of SEQ ID NO: 40. In some embodiments, the effector cell expressing a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof further comprises a P2A nucleic acid sequence encoding SEQ ID NOs: 13, 27, 41. In some embodiments, an effector cell (eg, T cell) expressing a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof on its surface is provided, comprising a nucleic acid sequence encoding an amino acid sequence of one or more of SEQ ID NOs: 14, 28, 42.

[0166] In some embodiments, the composition comprises an isolated MAGE-A1 TCR or antigen binding domain thereof, comprising a) a TCR α chain comprising the amino acid sequence of SEQ ID NO: 9 and b) a TCR β chain comprising the amino acid sequence of SEQ ID NO: 12; and / or c) a TCR α chain comprising the amino acid sequence of SEQ ID NO: 23 and d) a TCR β chain comprising the amino acid sequence of SEQ ID NO: 26; and / or e) a TCR α chain comprising the amino acid sequence of SEQ ID NO: 37 and f) a TCR β chain comprising the amino acid sequence of SEQ ID NO: 40. In some embodiments, the MAGE-A1 tumor-specific TCR or antigen binding domain thereof further comprises the P2A sequence of SEQ ID NOs: 13, 27, 41. In some embodiments, a MAGE-A1 tumor-specific TCR or antigen binding domain thereof is provided, comprising the amino acid sequence of one or more of SEQ ID NOs: 14, 28, 42.

[0167] In some embodiments, a method for treating a target antigen-related disease (e.g., cancer) in an individual in need thereof is provided, comprising administering to the individual an effective amount of a composition comprising an effector cell (e.g., T cell or natural killer cell) presenting a MAGE-A1 tumor-specific TCR or its antigen-binding domain (e.g., MAGE-A1 tumor-specific TCR or its antigen-binding domain) on the surface, wherein the target antigen of the effector cell (e.g., T cell) of the MAGE-A1 tumor-specific TCR is a MAGE-A1 peptide / MHC complex. In some embodiments, the MHC protein in the MAGE-A1 peptide / MHC complex is an MHC-I class protein. In some embodiments, the MHC-I class protein is HLA-A. In some embodiments, the effector cell is a γδT cell. In some embodiments, the effector cell is an αβT cell. In some embodiments, the effector cell is selected from the group consisting of a cytotoxic T cell, a helper T cell, a natural killer T cell, and a suppressor T cell. In some embodiments, the target antigen of the effector cell (eg, T cell) expressing a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof on its surface is MAGE-A1. 96-104Peptide / MHCI A*11:01 complex. The present invention also encompasses a method of treating a target antigen-related disease in an individual in need thereof, comprising administering to the individual a composition comprising a plurality of effector cells expressing different MAGE-A1 tumor-specific TCRs or their antigen-binding domains. Therefore, in some embodiments, according to any of the methods for treating a target antigen-related disease in an individual described herein, the composition is a heterogeneous MAGE-A1 tumor-specific TCR effector cell composition as described herein. For example, in some embodiments, a method of treating a target antigen-related disease (e.g., cancer) in an individual in need thereof is provided, comprising administering to the individual an effective amount of a heterogeneous MAGE-A1 tumor-specific TCR effector cell composition, the composition comprising a plurality of MAGE-A1 tumor-specific TCR effector cell populations according to any one of the embodiments described herein, wherein all MAGE-A1 tumor-specific TCR effector cells in the composition have the same cell type (e.g., all MAGE-A1 tumor-specific TCR effector cells are cytotoxic T cells), wherein each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR that is different from other MAGE-A1 tumor-specific TCR effector cell populations, and wherein at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR that specifically binds to the target antigen. In some embodiments, the MAGE-A1 tumor-specific TCR effector cell is a T cell. In some embodiments, the MAGE-A1 tumor-specific TCR effector cell is selected from the group consisting of a cytotoxic T cell, a helper T cell, a natural killer T cell, and a suppressor T cell. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a target antigen. In some embodiments, at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a different target antigen. In some embodiments, wherein at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a different target antigen, each of the different target antigens is associated with a target antigen-associated disease.

[0168] In some embodiments, a method for treating a target antigen-related disease (e.g., cancer) in an individual in need is provided, comprising administering to an individual an effective amount of a heterogeneous MAGE-A1 tumor-specific TCR effector cell composition, the composition comprising a plurality of MAGE-A1 tumor-specific TCR effector cell populations according to any one of the embodiments described herein, wherein at least one MAGE-A1 tumor-specific TCR effector cell population has a cell type different from other MAGE-A1 tumor-specific TCR effector cell populations, and wherein at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen-binding domain that specifically binds to a target antigen. In some embodiments, all MAGE-A1 tumor-specific TCR effector cell populations have different cell types. In some embodiments, MAGE-A1 tumor-specific TCR effector cells are T cells. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population has a cell type selected from cytotoxic T cells, helper T cells, natural killer T cells, and suppressor T cells. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population expresses the same MAGE-A1 tumor-specific TCR or its antigen binding domain. In some embodiments, at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that is different from other MAGE-A1 tumor-specific TCR effector cell populations. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that is different from other MAGE-A1 tumor-specific TCR effector cell populations. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to a target antigen. In some embodiments, at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to different target antigens. In some embodiments, at least one population of MAGE-A1 tumor-specific TCR effector cells expresses a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof that specifically binds to different target antigens, each of the different target antigens being associated with a target antigen-associated disease.

[0169] In some embodiments, a method of treating a disease associated with multiple target antigens in an individual in need thereof is provided, comprising administering to the individual an effective amount of a heterogeneous MAGE-A1 tumor-specific TCR effector cell composition, the composition comprising a plurality of MAGE-A1 tumor-specific TCR effector cell populations according to any of the embodiments described herein, wherein all MAGE-A1 tumor-specific TCR effector cells in the composition are of the same cell type (e.g., all MAGE-A1 tumor-specific TCR effector cells are cytotoxic T cells), wherein each MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that is different from other MAGE-A1 tumor-specific TCR effector cell populations, and wherein for each target antigen of the plurality of target antigens, at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen binding domain that specifically binds to the target antigen. In some embodiments, the MAGE-A1 tumor-specific TCR effector cells are T cells. In some embodiments, the MAGE-A1 tumor-specific TCR effector cells are selected from the group consisting of cytotoxic T cells, helper T cells, natural killer T cells, and suppressor T cells.

[0170] In some embodiments, a method for treating a disease associated with multiple target antigens in an individual in need is provided, comprising administering to an individual an effective amount of a heterogeneous MAGE-A1 tumor-specific TCR effector cell composition, the composition comprising a plurality of MAGE-A1 tumor-specific TCR effector cell populations according to any one of the embodiments described herein, wherein at least one MAGE-A1 tumor-specific TCR effector cell population has a cell type different from that of other MAGE-A1 tumor-specific TCR effector cell populations, and wherein for each of the plurality of target antigens, at least one MAGE-A1 tumor-specific TCR effector cell population expresses a MAGE-A1 tumor-specific TCR or its antigen-binding domain that specifically binds to the target antigen. In some embodiments, all MAGE-A1 tumor-specific TCR effector cell populations have different cell types. In some embodiments, the MAGE-A1 tumor-specific TCR effector cells are T cells. In some embodiments, each MAGE-A1 tumor-specific TCR effector cell population has a cell type selected from cytotoxic T cells, helper T cells, natural killer T cells, and suppressor T cells. In some embodiments, each population of MAGE-A1 tumor-specific TCR effector cells expresses a different MAGE-A1 tumor-specific TCR or antigen binding domain thereof than other populations of MAGE-A1 tumor-specific TCR effector cells.

[0171] In some embodiments, the individual is a mammal (e.g., human, non-human primate, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc.). In some embodiments, the individual is human. In some embodiments, the individual is a clinical patient, a clinical trial volunteer, an experimental animal, etc. In some embodiments, the individual is less than about 60 years old (including, for example, less than about 50, 40, 30, 25, 20, 15, or 10 years old). In some embodiments, the individual is older than about 60 years old (including, for example, older than about 70, 80, 90, or 100 years old). In some embodiments, the individual is diagnosed with or is environmentally or genetically susceptible to one or more of the diseases or disorders described herein (e.g., cancer). In some embodiments, the individual has one or more risk factors associated with one or more diseases or disorders described herein.

[0172] In some embodiments, the MAGE-A1 tumor-specific TCR effector cell composition of the present invention is administered in combination with a second, third, or fourth agent (including, for example, an anti-neoplastic agent, a growth inhibitor, a cytotoxic agent, or a chemotherapeutic agent) to treat a disease or condition involving target antigen expression. In some embodiments, the MAGE-A1 tumor-specific TCR effector cell composition is administered in combination with a cytokine (e.g., IL-2). In some embodiments, the MAGE-A1 tumor-specific TCR or its antigen-binding domain is administered in combination with an agent that increases MHC protein expression and / or enhances surface presentation of peptides by MHC proteins. In some embodiments, the agent includes, for example, an IFN receptor agonist, an Hsp90 inhibitor, a p53 expression enhancer, and a chemotherapeutic agent. In some embodiments, the agent is an IFN receptor agonist, including, for example, IFNγ, IFNβ, and IFNα. In some embodiments, the agent is an Hsp90 inhibitor, including, for example, tanespimycin (17-AAG), alvespimycin (17-DMAG), retaspimycin (IPI-504), IPI-493, CNF2024 / BIIB021, MPC-3100, Debio0932 (CUDC-305), PU-H71, Ganetespib (STA-9090), NVP-AUY922 (VER-52269), HSP990, KW-2478, AT13387, SNX-5422, DS-2248, and XL888. In some embodiments, the agent is a p53 expression enhancer, including, for example, 5-fluorouracil and nutlin-3. In some embodiments, the agent is a chemotherapeutic agent, including, for example, topotecan, etoposide, cisplatin, paclitaxel, and vinblastine. In some embodiments, a method for treating a target antigen-positive disease in an individual in need is provided, comprising administering to the individual a MAGE-A1 tumor-specific TCR effector cell composition according to any one of the embodiments described herein and a cytokine (e.g., IL-2). In some embodiments, the MAGE-A1 tumor-specific TCR effector cell composition and the cytokine are administered simultaneously. In some embodiments, the MAGE-A1 tumor-specific TCR effector cell composition and the cytokine are administered sequentially.

[0173] In some embodiments, a method for treating a target antigen-positive disease in an individual in need is provided, wherein cells expressing the target antigen generally do not present or present a complex comprising the target antigen and MHC class I proteins at a relatively low level on their surface, the method comprising administering to the individual a MAGE-A1 tumor-specific TCR effector cell composition according to any one of the embodiments described herein and an agent that increases the expression of MHC class I proteins and / or enhances the surface presentation of MHC class I proteins to the target antigen. In some embodiments, the agent includes, for example, an IFN receptor agonist, an Hsp90 inhibitor, a p53 expression enhancer, and a chemotherapeutic agent. In some embodiments, the agent is an IFN receptor agonist, including, for example, IFNγ, IFNβ, and IFNα. In some embodiments, the agent is an Hsp90 inhibitor, including, for example, tanspiramycin (17-AAG), aspiramycin (17-DMAG), retasmycin (IPI-504), IPI-493, CNF2024 / BIIB021, MPC-3100, Debio0932 (CUDC-305), PU-H71, galitepi (STA-9090), NVP-AUY922 (VER-52269), HSP990, KW-2478, AT13387, SNX-5422, DS-2248, and XL888. In some embodiments, the agent is a p53 expression enhancer, including, for example, 5-fluorouracil and nutlin-3. In some embodiments, the agent is a chemotherapeutic agent, including, for example, topotecan, etoposide, cisplatin, paclitaxel, and vinblastine. In some embodiments, the MAGE-A1 tumor-specific TCR effector cell composition and the agent are administered simultaneously. In some embodiments, the MAGE-A1 tumor-specific TCR effector cell composition and the agent are administered sequentially.

[0174] In some embodiments, a method of treating a target antigen-related disease (e.g., cancer) in an individual in need is provided, comprising administering to the individual an effective amount of a composition comprising a nucleic acid encoding a MAGE-A1 tumor-specific TCR or its antigen-binding domain according to any one of the embodiments described herein. Gene delivery methods are known in the art. See, e.g., U.S. Patents Nos. 5,399,346, 5,580,859, and 5,589,466, which are incorporated herein by reference in their entirety.

[0175] Cancer treatment can be assessed by, for example, tumor regression, reduction in tumor weight or size, percentage of cancer cell death, time to progression, duration of survival, progression-free survival, overall response rate, duration of response, quality of life, protein expression and / or activity. Methods for determining efficacy of therapy can be used, including, for example, measuring response via radiographic imaging.

[0176] In some embodiments, the therapeutic efficacy is measured as a percentage of tumor growth inhibition (TGI%), which is calculated using the formula 100-(T / C×100), where T is the average relative tumor volume of treated tumors and C is the average relative tumor volume of untreated tumors. In some embodiments, the TGI% is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, or greater than 95%.

[0177] In some embodiments, the therapeutic efficacy is measured as a percentage of tumor growth inhibition (TGI%), which is calculated using the formula 100-(T / C×100), where T is the number of treated target cells and C is the number of untreated target cells. In some embodiments, the TGI% is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, or greater than 95%.

[0178] In some embodiments, any of the methods of treating a target antigen-associated disease in an individual described herein is further combined with an immunosuppressant, a therapeutic antibody, chemotherapy, radiation therapy, surgery, or any combination thereof.

[0179] disease

[0180] In some embodiments, MAGE-A1 tumor-specific TCR effector cells may be useful for treating cancers associated with a target antigen. Cancers that can be treated using any of the methods described herein include non-vascularized, or tumors that are not substantially vascularized, and vascularized tumors. Cancers may comprise non-solid tumors (e.g., blood tumors, such as leukemias and lymphomas) or may comprise solid tumors. The types of cancers to be treated by the MAGE-A1 tumor-specific TCR effector cells of the present invention include, but are not limited to, carcinomas, blastomas, and sarcomas, and certain leukemias or lymphoid malignancies, benign and malignant tumors, and malignancies, such as sarcomas, carcinomas, and melanomas. Adult tumors / cancers and pediatric tumors / cancers are also included. Hematological cancers are cancers of the blood or bone marrow. Examples of blood (or bloody) cancers include leukemias, including acute leukemias (e.g., acute lymphocytic leukemia, acute myeloid leukemia, acute myeloid leukemia, and myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemias), chronic leukemias (e.g., chronic myeloid (granulocytic) leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia), polycythemia vera, lymphomas, Hodgkin's disease, non-Hodgkin's lymphomas (refractory and advanced forms), multiple myeloma, plasmacytoma, Waldenstrom's macroglobulinemia, heavy chain disease, myelodysplastic syndrome, hairy cell leukemia, and myelodysplasia. Solid tumors are abnormal tissue masses that usually do not contain cysts or fluid areas. Solid tumors can be benign or malignant. Different types of solid tumors are named after the type of cells that form them (eg, sarcoma, carcinoma, and lymphoma).Examples of solid tumors (e.g., sarcomas and carcinomas) include adrenocortical carcinoma, bile duct carcinoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma and other sarcomas, synovial tumors, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, gastric cancer, lymphoid malignancies, pancreatic cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, thyroid cancer (e.g., medullary thyroid carcinoma and papillary thyroid carcinoma), pheochromocytoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, branch Tracheal cancer, renal cell carcinoma, liver cancer, bile duct cancer, choriocarcinoma, Wilms' tumor, cervical cancer (e.g., cervical cancer and preinvasive cervical dysplasia), colorectal cancer, anal cancer, anal canal cancer or anorectal cancer, vaginal cancer, vulvar cancer (e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma and fibrosarcoma), penile cancer, oropharyngeal cancer, esophageal cancer, head cancer (e.g., squamous cell carcinoma), cervical cancer (e.g., squamous cell carcinoma), testicular cancer (e.g., seminoma, teratoma, embryonal carcinoma, teratoepithelioma, choriocarcinoma, sarcoma, Leydig cell tumor (e.g., The present invention relates to a group of tumors including hematopoietic stem cell tumors, fibromas, fibroadenomas, adenomatoid tumors, and lipomas), bladder cancer, kidney cancer, melanoma, uterine cancer (e.g., endometrial cancer), urothelial cancer (e.g., squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma, ureteral cancer, and bladder cancer), and CNS tumors (e.g., gliomas (e.g., brain stem gliomas and mixed gliomas), glioblastomas (also known as glioblastoma multimorphic), astrocytomas, CNS lymphomas, blastomas, medulloblastomas, schwannomas, craniopharyngiomas, ependymomas, pinealomas, hemangioblastomas, acoustic neuromas, oligodendrogliomas, meningiomas, neuroblastomas, retinoblastomas, and brain metastases).

[0181] Cancer treatment can be evaluated, for example, by tumor regression, reduction in tumor weight or size, time to progression, duration of survival, progression-free survival, overall response rate, duration of response, quality of life, protein expression and / or activity. Methods for determining efficacy of therapy can be used, including, for example, measuring response via radiographic imaging.

[0182] Products and kits

[0183] In some embodiments of the present invention, a product is provided, which contains materials suitable for treating target antigen-positive diseases, such as cancer (e.g., adrenocortical carcinoma, bladder cancer, breast cancer, cervical cancer, bile duct cancer, colorectal cancer, esophageal cancer, glioblastoma, glioma, hepatocellular carcinoma, head and neck cancer, kidney cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, pancreatic cancer, pheochromocytoma, plasma cell tumor, neuroblastoma, ovarian cancer, prostate cancer, sarcoma, gastric cancer, uterine cancer, or thyroid cancer). The product may include a container and a label or drug instruction sheet on or attached to the container. Suitable containers include, for example, bottles, vials, syringes, etc. The container can be formed of various materials, such as glass or plastic. In general, the container holds a composition that can effectively treat the diseases or conditions described herein, and may have a sterile access port (e.g., the container may be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic injection needle). At least one active agent in the composition is an effector cell presenting the MAGE-A1 tumor-specific TCR of the present invention or its antigen binding domain on its surface. The label or drug package insert indicates that the composition is used to treat a specific condition. The label or drug package insert will further contain instructions for administering the MAGE-A1 tumor-specific TCR effector cell composition to a patient. Articles and kits containing the combination therapies described herein are also contemplated.

[0184] Drug instructions refer to instructions that are usually included in the packaging of commercially available therapeutic products, containing instructions about indications, uses, dosages, administration, contraindications and / or warnings related to the use of such therapeutic products. In some embodiments, the drug instructions indicate that the composition is used to treat target antigen-positive cancers (e.g., adrenocortical carcinoma, bladder cancer, breast cancer, cervical cancer, bile duct cancer, colorectal cancer, esophageal cancer, glioblastoma, glioma, hepatocellular carcinoma, head and neck cancer, kidney cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, pancreatic cancer, pheochromocytoma, plasmacytoma, neuroblastoma, ovarian cancer, prostate cancer, sarcoma, gastric cancer, uterine cancer, or thyroid cancer). In addition, the product may further include a second container, which includes a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other substances required from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.

[0185] Also provided are kits suitable for various purposes, such as for treating target antigen-positive diseases or disorders described herein, optionally in combination with products. The kits of the present invention include one or more containers comprising a MAGE-A1 tumor-specific TCR effector cell composition (or unit dosage form and / or product), and in some embodiments, further comprising another agent (such as an agent described herein) and / or instructions for use according to any of the methods described herein. The kit may further include instructions for selecting individuals suitable for treatment. The instructions provided in the kit of the present invention are written instructions typically on a label or drug instruction sheet (e.g., a paper sheet included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetized or optical storage disc) are also acceptable.

[0186] For example, in some embodiments, the kit comprises a composition comprising effector cells presenting MAGE-A1 tumor-specific TCRs on their surface. In some embodiments, the kit comprises a) a composition comprising effector cells presenting MAGE-A1 tumor-specific TCRs or their antigen-binding domains on their surface, and b) an effective amount of at least one other agent, wherein the other agent increases the expression of MHC proteins and / or enhances the surface presentation of peptides by MHC proteins (e.g., IFNγ, IFNβ, IFNα, or Hsp90 inhibitors). In some embodiments, the kit comprises a) a composition comprising effector cells presenting MAGE-A1 tumor-specific TCRs or their antigen-binding domains on their surface, and b) administering to an individual

[0187] Instructions for administering a MAGE-A1 tumor-specific TCR effector cell composition to treat a target cell-positive disease (e.g., cancer). In some embodiments, the kit comprises a) a composition comprising effector cells presenting a MAGE-A1 tumor-specific TCR or its antigen-binding domain on the surface, b) an effective amount of at least one other agent, wherein the other agent increases the expression of MHC proteins and / or enhances the surface presentation of peptides by MHC proteins (e.g., IFNγ, IFNβ, IFNα, or Hsp90 inhibitors), and c) instructions for administering a MAGE-A1 tumor-specific TCR effector cell composition and other agents to an individual to treat a target cell-positive disease (e.g., cancer). The MAGE-A1 tumor-specific TCR effector cell composition and other agents may be present in separate containers or in a single container. For example, a kit may comprise a unique composition or two or more compositions, wherein one composition comprises a MAGE-A1 tumor-specific TCR effector cell and another composition comprises another agent.

[0188] In some embodiments, the kit comprises a) a composition comprising a MAGE-A1 tumor-specific TCR or an antigen binding domain thereof, and b) instructions for combining a MAGE-A1 tumor-specific TCR or an antigen binding domain thereof with an effector cell (e.g., an effector cell derived from an individual, such as a T cell or a natural killer cell) to form a composition comprising an effector cell presenting a MAGE-A1 tumor-specific TCR or an antigen binding domain thereof on its surface and administering the MAGE-A1 tumor-specific TCR effector cell composition to an individual to treat a target antigen-positive disease (e.g., cancer). In some embodiments, the kit comprises a) a composition comprising a MAGE-A1 tumor-specific TCR or an antigen binding domain thereof, and b) an effector cell (e.g., a cytotoxic cell). In some embodiments, the kit comprises a) a composition comprising a MAGE-A1 tumor-specific TCR or an antigen binding domain thereof, b) effector cells (e.g., cytotoxic cells), and c) instructions for combining the MAGE-A1 tumor-specific TCR or an antigen binding domain thereof with the effector cells to form a composition comprising effector cells presenting the MAGE-A1 tumor-specific TCR or an antigen binding domain thereof on their surface and administering the MAGE-A1 tumor-specific TCR effector cell composition to a subject to treat a target antigen-positive disease (e.g., cancer).

[0189] In some embodiments, the kit comprises a nucleic acid (or a set of nucleic acids) encoding a MAGE-A1 tumor-specific TCR or its antigen binding domain. In some embodiments, the kit comprises a) a nucleic acid (or a set of nucleic acids) encoding a MAGE-A1 tumor-specific TCR or its antigen binding domain, and b) a host cell (e.g., an effector cell) for expressing the nucleic acid (or the set of nucleic acids). In some embodiments, the kit comprises a) a nucleic acid (or a set of nucleic acids) encoding a MAGE-A1 tumor-specific TCR or its antigen binding domain, and b) instructions for i) expressing a MAGE-A1 tumor-specific TCR or its antigen binding domain in a host cell (e.g., an effector cell, such as a T cell), ii) preparing a composition comprising a host cell expressing a MAGE-A1 tumor-specific TCR or its antigen binding domain, and iii) administering a composition comprising a host cell expressing a MAGE-A1 tumor-specific TCR or its antigen binding domain to an individual to treat a target antigen-positive disease (e.g., cancer). In some embodiments, the host cell is derived from an individual. In some embodiments, the kit comprises a) a nucleic acid (or a set of nucleic acids) encoding a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof, b) a host cell (e.g., an effector cell) for expressing the nucleic acid (or the set of nucleic acids), and c) instructions for i) expressing a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof in a host cell, ii) preparing a composition comprising a host cell expressing a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof, and iii) administering a composition comprising a host cell expressing a MAGE-A1 tumor-specific TCR or an antigen-binding domain thereof to an individual to treat a target antigen-positive disease (e.g., cancer). The kit of the present invention is in a suitable package. Suitable packages include, but are not limited to, vials, bottles, cans, plastic packaging (e.g., sealed Mylar or plastic bags), and the like. The kit may optionally provide additional components such as buffers and descriptive information. The present application therefore also provides articles of manufacture, which include vials (e.g., sealed vials), bottles, cans, plastic packaging, and the like.

[0190] Instructions for use of the MAGE-A1 tumor-specific TCR effector cell composition generally include information about the dosage, dosing schedule, and route of administration for the desired treatment. The container may be a unit dose, bulk (e.g., multi-dose packaging), or a sub-unit dose. For example, a kit containing a sufficient dose of a MAGE-A1 tumor-specific TCR effector cell composition as disclosed herein may be provided to provide an individual with effective treatment for a longer period of time, such as one week, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or any one of longer periods.

[0191] The kit may also include multiple unit doses of the MAGE-A1 tumor-specific TCR or antigen binding domain thereof and the pharmaceutical composition and instructions for use and packaged in quantities sufficient for storage and use in pharmacies, such as hospital pharmacies and compounding pharmacies.

[0192] Those skilled in the art will recognize that within the scope and spirit of the present invention, several embodiments are possible. The present invention will now be described in more detail with reference to the following non-limiting examples. The following embodiments further illustrate the present invention, but certainly should not be construed as limiting its scope in any way. It should be understood that one, some, or all of the properties of the various embodiments described herein may be combined to form other embodiments of the present invention. Example

[0193] The following examples are intended to be purely illustrative of the present patent application and therefore should not be considered to limit the invention in any way.The following examples and detailed description are provided by way of illustration and not by way of limitation.

[0194] Example 1: Preparation of MAGE-A1-specific T cells

[0195] A MAGE-A1 antigen-specific T cell receptor HRYZ-TCR-4.12 was prepared for characterization and validation experiments. For each tumor antigen-specific T cell receptor, a human (i.e., wild-type) TCR construct and a murinized TCR construct corresponding to it were prepared; codon optimization was performed for HRYZ-TCR-4.12. The murinized TCR construct has murine constant domains (mCα and mCβ1). Schematic diagrams of wild-type, murinized, and murinized codon-optimized constructs of tumor antigen-specific T cell receptors are shown in Figure 1 shown.

[0196] Example 2: Validation of MAGE-A1-specific T cell receptor HRYZ-TCR-4.12

[0197] The purpose of this example is to verify the expression, peptide recognition, epitope recognition, HLA blocking, and in vitro toxicity of the T cell receptor (TCR) HRYZ-TCR-4.12.

[0198] TCR expression and peptide recognition assay

[0199] TCR expression and peptide recognition assays such as Figure 2 shown.

[0200] TCR expression was assessed using a FACS assay that detected stained TCR Vβ chains. Briefly, TCR-transferred T cells were collected and washed by adding 10 mL PBS (containing 2% fetal bovine serum), centrifuged at 350 g for 5 minutes, and the supernatant was completely aspirated. The cell pellet was resuspended and adjusted to approximately 2×10 by adding PBS (containing 2% fetal bovine serum). 6 100 μL / sample of the cell suspension was collected and used for TCR Vβ chain surface staining and detection by FACS.

[0201] Using MAGE-A1 96-104 Peptide determination of TCR-transduced T cells for MAGE-A1 recognition. TCR-transduced T cells were collected and washed by adding 10 mL of PBS, centrifuged at 350 g for 5 minutes, and the supernatant was completely aspirated. Then, TCR-transduced T cells were resuspended by adding AIM-V medium (containing 10% fetal bovine serum) and adjusted to 1×10 6 cells / mL in a 96-well plate. 96-104 The peptides were mixed with tumor-specific T cells, brefeldin A (final concentration 3 μg / mL) was added to the wells and cultured for 4 hours. After 4 hours, the cells were collected and used for intracellular IFN-γ and CD3 staining and detected by FACS. For IFN-γ ELISA detection, 100 μL / well of LCL (1×10 6 cells / mL) and 100 μL / well of TCR-transduced T cells (1×10 6 Cells / mL) were mixed into a 96-well plate and cultured in an incubator for 24 hours. After 24 hours, 175 μL of supernatant was collected from each well of the 96-well plate and used for ELISA detection of IFN-γ using an IFN-γ ELISA HRP kit.

[0202] like Figure 3-4 As shown, HRYZ-TCR-4.12 can specifically recognize the peptide MAGE-A1 96-104 .

[0203] LCL stimulation assay for validation of epitope recognition

[0204] The LCL stimulation assay was performed as follows. First, LCLs were loaded with peptides: LCLs were collected in a 15 mL tube, washed by adding 10 mL PBS, centrifuged at 350 g for 5 minutes, and the supernatant was completely aspirated. The cell pellet was resuspended in culture medium (RPMI1640 containing 10% FBS) and adjusted to 1×10 6 The tumor antigen peptide was added to LCL to a final concentration of 5 μg / mL and cultured in an incubator for 8 to 24 hours. Then, TCR-T cells were stimulated with peptide-loaded LCL as follows: the peptide-loaded LCL was collected and washed by adding 10 mL of PBS, centrifuged at 350 g for 5 minutes, and the supernatant was completely aspirated. The LCL was resuspended and adjusted to 1×10 by adding AIM-V medium (containing 10% fetal bovine serum). 6 TCR-transduced T cells were collected and washed by adding 10 mL of PBS, centrifuged at 350 g for 5 minutes, and the supernatant was completely aspirated. Then, TCR-transduced T cells were resuspended by adding AIM-V medium (containing 10% fetal bovine serum) and adjusted to 1×10 6 100 μL / well of LCL (1×10 6 cells / mL) and 100 μL / well of TCR-transduced T cells (1×10 6 Cells / mL) were mixed into a 96-well plate and cultured in an incubator for 24 hours. After 24 hours, 175 μL of supernatant was collected from each well of the 96-well plate and used for ELISA detection of IFN-γ using an IFN-γ ELISA HRP kit.

[0205] HLA restriction assay

[0206] Cells with various HLA-A subtypes are loaded with MAGE-A1 96-104 Peptides were used to stimulate T cells transfected with T cell receptors in HLA restriction assays. Wash by adding 10 mL of PBS, centrifuge at 350 g for 5 minutes, and aspirate the supernatant completely. Resuspend the cell pellet by adding AIM-V medium (containing 10% fetal bovine serum) and adjust to 1×10 6 Cells / mL. 100 μL / well of the cell suspension was added to a 96-well plate, and HLA blocking antibodies (final concentration 50 μg / mL) were added to the appropriate wells and cultured in an incubator for 2 hours. TCR-transferred T cells were collected, washed by adding 10 mL of PBS, centrifuged at 350 g for 5 minutes, and the supernatant was completely aspirated. Cell clumps were collected and adjusted to 1×10 by adding AIM-V medium (containing 10% fetal bovine serum). 6cells / mL. 100 μL / well of TCR-transduced cell suspension was added to the corresponding wells, mixed with LCLs, and cultured in an incubator for 24 hours. After 24 hours, 175 μL of supernatant was collected from each well of the 96-plate and finally measured using human IFN-γ ELISA.

[0207] On day 1, high protein binding ELISA plates were coated with antibody 1-D1K (IFN-γ ELISA HRP kit) diluted to 2 μg / mL in PBS (pH 7.4) (by adding 50 μL / well) and incubated overnight at 4°C. On day 2, the plates were washed twice with PBS (200 μL / well). The plates were blocked by adding 200 μL / well of culture medium and incubated for 1 hour at room temperature (RT). Human IFN-γ standards (IFN-γ ELISA HRP kit) were prepared in 2 mL PBS (with 1% BSA) to a concentration of 0.5 μg / mL and placed at RT for 15 minutes, then the tubes were vortexed. 50 μL / well of samples or standards were diluted in culture medium and incubated for 2 hours at RT. Samples and standard probes were tested in duplicate. The plates were washed five times with PBS containing 0.05% Tween20. Add 50 μL / well of antibody 7-B6-1-biotin (IFN-γ ELISA HRP kit) at 1 μg / mL (in PBS), incubate for 1 hour at RT, and wash. Add 50 μL / well of streptavidin-HRP (IFN-γ ELISA HRP kit) diluted 1:1000 in PBS, incubate for 1 hour at RT, and wash. Add 100 μL / well of TMB substrate solution and incubate in the dark at RT for 15 to 30 minutes until the solution in the well turns visible blue. Add 50 μL / well of stop solution to stop the enzyme reaction. The solution color changes from blue to yellow. Measure the light intensity with an ELISA reader at 450 nm.

[0208] like Figure 5 As shown, T cells transfected with HRYZ-TCR-4.12 can recognize MAGE-A1 presented by HLA-A*11:01 96-104 Antigenic peptide.

[0209] In vitro toxicity assay

[0210] T cells transfected with T cell receptor HRYZ-TCR-4.12 were used as effector cells and mixed with target cells at a ratio of 5:1 as the experimental group. The target cells used in this experiment were A549 cells transfected with HLA-A*11:01 and MAGE-A1 proteins. T cells not transfected with T cell receptors were mixed with target cells at the same ratio as the control group. The killing ability of effector cells in the experimental group and the control group on target cells was continuously measured for 48 hours.

[0211] like Figure 6 As shown, T cells transfected with HRYZ-TCR-4.12 had a significant killing effect on A549 target cells expressing HLA-A*11:01 and MAGE-A1 proteins, and 90.7% of the target cells were killed. In the control group, untransfected T cells had no killing effect on target cells.

[0212] CDR sequences of TCRs of the present invention

[0213]

[0214] The sequence involved in the present invention is as follows

[0215]

[0216]

[0217]

[0218]

[0219]

[0220]

[0221]

[0222]

[0223]

[0224]

[0225]

Claims

1. An isolated tumor-specific T cell receptor (TCR) or an antigen binding domain thereof that specifically binds to a major histocompatibility complex (MHC) / MAGE-A1 epitope complex, wherein the tumor-specific TCR comprises: A TCR alpha chain comprising a CDR1 of the amino acid sequence of SEQ ID NO: 1, a CDR2 of the amino acid sequence of SEQ ID NO: 2, and a CDR3 of the amino acid sequence of SEQ ID NO: 3; and a TCR β chain comprising a CDR1 of the amino acid sequence of SEQ ID NO:4, a CDR2 of the amino acid sequence of SEQ ID NO:5, and a CDR3 of the amino acid sequence of SEQ ID NO:

6.

2. The isolated tumor-specific TCR or antigen-binding domain thereof according to claim 1, wherein the MAGE-A1 epitope is the amino acid sequence shown in SEQ ID NO:

79.

3. The isolated tumor-specific TCR or antigen binding domain thereof of claim 1 or 2, wherein the MHC is HLA-A*11:

01.

4. The isolated tumor-specific TCR or antigen-binding domain thereof of claim 1, comprising: A TCR alpha chain comprising a variable region of the amino acid sequence of SEQ ID NO:7, and a TCR beta chain comprising a variable region of the amino acid sequence of SEQ ID NO:

10.

5. The isolated tumor-specific TCR or antigen-binding domain thereof of claim 1, comprising: A TCR alpha chain comprising the amino acid sequence of SEQ ID NOs: 7 and 8, and a TCR beta chain comprising the amino acid sequence of SEQ ID NOs: 10 and 11 or an amino acid sequence having at least 90% sequence identity thereto.

6. The isolated TCR or antigen binding domain thereof according to claim 1, which is isolated or purified or recombinant.

7. The isolated TCR or antigen binding domain thereof according to claim 1, which is chimeric, humanized or human.

8. The isolated TCR or antigen binding domain thereof according to claim 1, wherein the TCR or antigen binding domain thereof is a single chain.

9. The isolated TCR or antigen binding domain thereof according to claim 8, wherein the TCR alpha chain further comprises an alpha constant (Calpha) region and / or the TCR beta chain further comprises a beta constant (Cbeta) region.

10. The isolated TCR or antigen binding domain thereof according to claim 9, wherein the Ca region and the Cβ region are mouse constant regions.

11. An isolated TCR or antigen-binding domain thereof according to claim 10, wherein the Cα region comprises the amino acid sequence of SEQ ID NO (Cα): 22 or an amino acid sequence having at least 90% sequence identity thereto, and / or the Cβ region comprises the amino acid sequence of SEQ ID NO (Cβ): 25 or an amino acid sequence having at least 90% sequence identity thereto.

12. The isolated TCR or antigen binding domain thereof according to claim 11, comprising: A TCR alpha chain comprising the amino acid sequence of SEQ ID NOs: 21 and 22 or an amino acid sequence having at least 90% sequence identity thereto, and a TCR beta chain comprising the amino acid sequence of SEQ ID NOs: 24 and 25 or an amino acid sequence having at least 90% sequence identity thereto.

13. The isolated TCR or antigen binding domain thereof according to claim 1, wherein the TCR alpha chain and / or the TCR beta chain further comprises a signal peptide.

14. An isolated nucleic acid molecule encoding the TCR alpha chain and TCR beta chain of the isolated TCR or antigen binding domain thereof according to any one of claims 1 to 13 above.

15. The isolated nucleic acid molecule of claim 14, wherein the nucleic acid sequence is codon optimized.

16. The isolated nucleic acid molecule according to claim 14 or 15, wherein the nucleotide sequence encoding the TCR alpha chain and the nucleotide sequence encoding the TCR beta chain are separated by a self-cleaving peptide sequence.

17. The isolated nucleic acid molecule according to claim 16, wherein the self-cleaving peptide is P2A, comprising the amino acid sequence shown in SEQ ID NOs:

13.

18. An engineered immune cell, wherein the engineered immune cell comprises the isolated TCR or its antigen binding domain described in any one of claims 1-13 or the isolated nucleic acid molecule described in any one of claims 14-17, wherein the engineered cell is a cell line or a primary cell obtained from a subject or an allogeneic cell.

19. The engineered immune cell of claim 18, wherein the immune cell is a human cell, including but not limited to a T cell, a NK cell, a macrophage.

20. The engineered immune cell of claim 19, wherein the immune cell is a T cell.

21. The engineered immune cell of claim 20, wherein the engineered cell comprises a CD8+ T cell.

22. The engineered immune cell of claim 20, wherein the engineered cell comprises a CD4+ T cell.

23. A pharmaceutical composition comprising the engineered immune cell according to claim 21 or 22, and a pharmaceutically acceptable carrier.

24. Use of the engineered immune cell of claim 18 in the preparation of a medicament for treating a disease or condition expressing MAGE-A1.

25. The use according to claim 24, wherein the disease or disorder is cancer.

26. The use according to claim 25, wherein the cancer is selected from the group consisting of lung cancer, liver cancer, skin cancer, breast cancer and head and neck tumors.

27. The use according to any one of claims 24 to 26, wherein the engineered cells are autologous cells or allogeneic cells of the subject.

28. The use according to claim 24, further comprising administering one or more of the following to the subject to which the engineered immune cells are administered: immunosuppressants, therapeutic antibodies, chemotherapy, radiotherapy, surgery, or any combination thereof.